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Abstract
The research described in this dissertation consists of three 
projects. In the first, I investigate of the impact of genome-wide 
heterozygosity on overall longevity in humans and estimate that within a 
single population, every standard deviation of heterozygosity an 
individual has over the mean decreases that person’s risk of death within 
a given time period by 1.57%. Our data shows this to be true even if the 
population itself has reduced mean heterozygosity and this effect is 
constant between ancestry, sex, and cause of death. In the second 
project, I investigate of the role of coding variants in regulating QT 
interval, a predictor of sudden cardiac death (SCD), and identify 10 novel 
loci associated with QT interval, and highlight the role of 17 specific 
genes. Our analyses also highlight a role for the internal structure and 
the interconnection of myocytes in modulating QT interval duration in 
addition to previously implicated pathways. In the last project, I 
investigate of the utility of genetics in predicting implantable 
cardioverter-defibrillator (ICD) therapy incidence. Unfortunately, our 
sample size was too limited to find meaningful results. To remedy this, 
we are working on building a consortium to increase sample size.
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Discussed herein are three projects I undertook broadly in the field 
of human genetics. The first is an investigation of the impact of genome-
wide heterozygosity on overall longevity in humans. In this case we refer 
to the lower risk of death within a time period as “longevity.” The 
presence of numerous genetic variants with small effects on health and 
related traits raises the question of whether aggregate measures of 
genomic variation are associated with human health and disease. 
Previous studies have found increased genetic diversity associated with 
increased fitness across many organisms (Mitton and Grant; Alibert et 
al.), including humans (Roberts et al.; Coetzee et al.; Campbell et al.; 
Takata et al.). Two general mechanisms that act at a genome level to 
influence fitness have been proposed: Compensation for recessive 
deleterious mutations and a specific advantage of the heterozygous state 
over either homozygous state, called overdominance or heterozygous 
advantage (Charlesworth and Willis). To test for the effect of genome-wide 
heterozygosity on survival, we performed a meta-analysis of 17 cohorts 
(13 European ancestry, 4 African American ancestry) followed 
prospectively, with a combined sample size of 46,716 individuals, 
including a total of 15,234 deaths and an average age at death of 80 
years old. This project is concerned with human genetics at a population 
level. We ask the question whether an individual's heterozygosity as 
compared his/her own genetic population is associated with the 
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individual’s survival over time. Participants are followed until death. Due 
to about 2/3 of participants still being alive, we used the most recent 
available follow up data, however the individual cohort studies are still 
on going and these results could be updated with additional follow up 
data in 10 years or so. The Cox Proportional Hazards (CoxPH) model we 
use handles this gracefully by censoring participants at time of last 
follow up. Since the average age at death in this study is over the life 
expectancy in the areas studied, we feel this is a legitimate longevity 
study. It is not a goal of this study to dissect the association to locate the 
underlying genetic and biologic causes or identify genes and pathways 
that contribute to the association.
The second project is an investigation of the role of coding variants 
in regulating QT Interval, a predictor of SCD. QT interval, determined via 
a standard non-invasive electrocardiogram (EKG) by measuring the time 
between the beginning of the Q deflection to the termination of the T 
wave, is a classic measure of ventricular repolarization time. Prolonged 
QT interval has been linked to higher risk of SCD, with between 180,000 
and 450,000 cases of SCD in the United States of America annually (Deo 
and Albert). Since the vast majority of SCD occurs in the absence of 
clinical features that would bring a victim to medical attention (Chugh et 
al.), identifying additional risk factors and dissecting the etiology of 
disease is of high importance. We conduct analyses across the Illumina 
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ExomeChip in population-based samples to interrogate the role of a 
largely unstudied class of variation on ventricular repolarization time in 
the population – coding variants. These variants fill in the gap between 
the extremely rare large-effect coding variants that result in the 
Mendelian long QT syndrome and short QT syndrome and the common 
small-effect largely non-coding variation identified through genome-wide 
association studies. The focus on exons and coding variants has an 
added benefit, in that genes can be directly implicated if LD is controlled 
for, whereas non-coding variation typically only implicates a region of the 
genome, often containing multiple genes, requiring extensive functional 
experiments to directly implicate a gene. We performed a meta-analysis 
of 241,552 variants in 17,574 genes in a sample of 95,626 individuals 
from 23 cohorts (comprised of 83,884 European ancestry individuals, 
9,610 African Americans, 1,382 Hispanics, and 750 Asian individuals) 
This project focuses on a particular disease, SCD, by looking at one of its 
related phenotypes, QT interval, and applies human genetics to 
understand an individual’s risk for this disease. The goal is finding 
individual genes that control electrophysiology and by extension affect a 
person’s risk for SCD. This represents a narrowing of focus compared to 
the population-based question in the first project. Once genes are 
identified, they become therapeutic targets and further investigations 
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could lead to treatments to prevent SCD. The information we learn can 
also be used to assess risk of SCD in high-risk populations.
Finally, the third project is an investigation of the utility of genetics 
in predicting ICD therapy incidence. An accurate prediction would be 
useful for evaluating if a particular patient should undergo surgery to 
receive an ICD. ICDs are devices that can prevent SCD in patients with 
systolic heart failure. As stated previously, there are between 180,000 
and 450,000 cases of SCD in the United States of America annually (Deo 
and Albert). The World Society of Arrhythmia found that there were 
133,262 ICD implants in the United States in 2009 alone (Mond and 
Proclemer). However, ICDs administer therapy in only a minority of 
people in which they are implanted, about 20% in our data. This 
represents a significant shortcoming in the clinical selection criteria for 
patients at greatest risk for SCD. We wish to find out whether we can use 
genetics to predict if an ICD will benefit a patient. This project is 
concerned with applying human genetics to a clinical question. The 
answer to this question could directly affect the actions taken by medical 
doctors with regard to the manner which they treated patients. This is 
the narrowest focus across the three projects and could have a direct 
effect on people’s lives.
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Chapter 2: Heterozygosity and Longevity
2.1 Abstract
Background: It has been well-established, both by population 
genetics theory and direct observation in many organisms, that increased 
genetic diversity provides a survival advantage. However, given the 
limitations of both sample size and genome-wide metrics, this hypothesis 
has not been comprehensively tested in human populations. Moreover, 
the presence of numerous segregating small effect alleles that influence 
traits that directly impact health directly raises the question as to 
whether global measures of genomic variation are themselves associated 
with human health and disease.
Results: We performed a meta-analysis of 17 cohorts followed 
prospectively, with a combined sample size of 46,716 individuals, 
including a total of 15,234 deaths and an average age at death of 80 
years old. We find a significant association between increased 
heterozygosity and survival (P=0.03). We estimate that within a single 
population, every standard deviation of heterozygosity an individual has 
over the mean decreases that person’s risk of death within a given time 
period by 1.57%.
Conclusions: This effect was consistent between European and 
African ancestry cohorts, men and women, and major causes of death 
(cancer and cardiovascular disease), demonstrating the broad positive 
impact of genomic diversity on human survival.
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2.2 Background
With the advent of genome-wide association studies (GWAS), and 
more recently whole-exome and whole-genome sequencing, remarkable 
progress has been made in elucidating the genetics of complex traits. 
Numerous genetic variants, each explaining a small fraction of the 
phenotypic variance, have been identified (“OMIM”; Hindorff et al.). The 
presence in the genome of numerous segregating small effect alleles that 
influence health related traits raises the question of whether global 
measures of genomic variation are themselves associated with human 
health and disease. Indeed, increased fitness has been associated with 
the increase of genetic diversity across many organisms (Mitton and 
Grant; Alibert et al.), including humans (Roberts et al.; Coetzee et al.; 
Campbell et al.; Takata et al.), and is often referred to as positive 
Heterozygosity Fitness Correlations (HFCs). In particular, associations 
have been found between heterozygosity at the Major Histocompatibility 
Complex (MHC) (a.k.a. Human Leukocyte Antigen, HLA) region and 
general health in humans (Lie, Simmons, and Rhodes). In the case of 
heterozygosity in the MHC region, the cause of a positive HFC being 
observed is believed to be the result of increased antibody diversity 
conveying more robust pathogen resistance and therefore increased 
general health (Piertney and Oliver). However, in the case of increased 
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whole-genome heterozygosity, the mechanism of action is less readily 
apparent. Two general mechanisms that act at a genome level to 
influence fitness have been proposed. The first is compensation for 
recessive deleterious mutations (Charlesworth and Willis), whereas the 
second is a specific advantage of the heterozygous state over either 
homozygous state (overdominance/heterozygous advantage) 
(Charlesworth and Willis), such as that observed for the sickle cell 
mutation in the presence of endemic malarial disease. It has been 
proposed that compensation for deleterious mutations occurs at many 
loci and is the major mechanism at work in HFCs, with overdominance 
occurring at few loci but with greater effect size per occurrence 
(Charlesworth and Willis).
2.3 Results and Discussion
Various heterozygosity metrics have been proposed (Szulkin, 
Bierne, and David). The heterozygosity metric used in this study is the 
sum of all heterozygous loci divided by the expected state given the allele 
frequency under Hardy-Weinberg Equilibrium: t=
∑ 0 ;1
∑ 2 p(1−p)
 where p 
is the frequency of the major allele in each cohort. This metric up-
weights loci where the expectation of being heterozygous is low. Given 
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the relationship between effect size and allele frequency (Arking and 
Chakravarti; Hindorff, Gillanders, and Manolio), up-weighting loci with 
low minor allele frequencies should maximize the ability to detect a HFC 
in humans under a model in which the compensation for deleterious 
alleles is the major mechanism driving HFCs. Only Single Nucleotide 
Polymorphisms (SNPs) on the autosomes were considered.
To test for the effect of genome-wide heterozygosity on survival, we 
performed a meta-analysis of 17 cohorts (13 European ancestry, 4 
African American ancestry) followed prospectively, with a combined 
sample size of 46,716 individuals, including a total of 15,234 deaths and 
an average age at death of 80 years old (Table 2.1). Within each cohort, a 
CoxPH was used comparing age at study entry to age at study exit 
(death) or most recent follow-up (alive), and included covariates known to 
affect survival (sex, highest education level, Body Mass Index (BMI), 
income level, center where DNA was collected, and the first ten principal 
components to adjust for population substructure). Since each cohort 
used a different number of SNPs (Table 2.1), the variances of the 
heterozygosity metrics are not the same (they are dependent on the total 
number of SNPs in the metric), and effect sizes from each cohort are not 
directly comparable. Using Stouffer's method to combine Z-scores, 
weighted by the number of deaths in each cohort, we find a significant 
association between increased heterozygosity and survival (P= 0.03). To 
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assess effect size, we standardized the beta estimates by multiplying 
them by the standard deviation of the heterozygosity metric for each 
cohort (Menard). This method does not completely account for the 
aforementioned bias; however, it is the most appropriate method to 
determine an interpretable effect size. Combining the standardized beta 
estimates using inverse variance weighting demonstrates that for every 
standard deviation increase in heterozygosity a person has over the 
population mean, they are expected to have a 1.57% decreased risk of 
death within a given time period (Figure 2.1). There was no evidence for 
heterogeneity across studies, and a direct comparison of European 
Ancestry to African ancestry cohorts showed no significant difference 
(Figure 2.2, P=0.80); thus, all downstream analyses combined European 
and African ancestry cohorts.
To test whether all chromosomes are contributing equally to the 
association between heterozygosity and survival, each study subject’s 
heterozygosity score was recalculated using only SNPs from a given 
chromosome. An inverse-variance meta-analysis for each chromosome 
was performed across studies, followed by a meta-analysis of the 
chromosomal results (Figure 2.3). No significant difference was observed 
between effects across chromosomes (P=0.17). To test whether all major 
causes of death contribute equally to our genome-wide finding, death 
caused by cancer, death caused by CVD, and other causes of death were 
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each analyzed separately. A meta-analysis for each cause of death was 
performed as described above, followed by a test for heterogeneity and 
model fitting. Our results demonstrate that heterozygosity is protective 
for all causes of death, with no significant evidence for heterogeneity 
(Figure 2.4, P=0.79). To assess if heterozygosity levels impact women 
differently from men, meta-analyses were performed separately for each 
sex. Our results do not provide evidence for a differential effect of 
heterozygosity on survival in men vs. women (Figure 2.5, P=0.49).
2.4 Conclusions
In summary, this study provides evidence that the protective effect 
of increased heterozygosity seen in lower organisms functions in humans 
as well and may have implications for how we design future studies to 
identify genetic determinants of human disease and survival. We 
estimate that within a single population, every standard deviation of 
heterozygosity an individual has over the mean decreases that person’s 
risk of death within a given time period by 1.57%. Interestingly, this 
seems to be true even if the population itself has reduced mean 
heterozygosity. In future studies, limiting to heterozygosity in proximity 
to genes and/or regulatory elements may reveal if some regions are more 
sensitive to heterozygosity than others. Increasing the African ancestry 
sample size may increase power to see a difference between ancestry 
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groups. Overall the consistency we observed between European and 
African ancestry, males and females, and major causes of death 
demonstrate a broad positive impact of genomic diversity on human 
survival.
2.5 Tables
Table 2.1: Cohort Demographics
Included here is a descriptive breakdown of each cohort and summary 
statistics.
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Study Name AGES ARIC CHS FHS HealthABC
Number Samples 3209 7825 3338 4526 1448
Number Deaths 1021 1878 2220 1332 764
Percent Female 58% 53% 60.3% 54.90% 45.86%
Mean baseline Body Mass Index (BMI) 27.11 26.92 N/A 27.78 26.59
Mean followup time (Years) 7.66 19.39 13.4 9.14 10.93
Mean Age at Death (Years) 84.58 73.60 84.63 81.71 83.34
Years of baseline examinations 2002-2007 1987-1989 1989-1990 1974-2006 1997-1998
Years of DNA collection 2002-2007 1987-1998 1989-1990 1974-2006 1997-1998
Array type Illumina Hu370CNV Affymetrix 6.0 Illumina 370CNV Affymetrix 500K mapping array, 
Affymetrix 50K supplemental 
gene-focused array
Illumina 1M
Genotype calling algorithm BeadStudio Birdseed BeadStudio BRLMM GenomeStudio
Data handling and statistical tests PLINK and R PLINK and R PLINK and R PLINK, R and SAS PLINK and R
Education Level 1 (N) <11th grade (769) <11th grade (1141) <11th grade (856) <11th grade (1315) for those reporting grade 11 or less, 
also for those reporting 
vocation/trade school without GED 
(174)
Education Level 2 (N) High school diploma, 
general equivalence 
diploma or some 
vocational school (1589)
High school diploma, 
general equivalence 
diploma or some 
vocational school (3686)
High school diploma, 
general equivalence 
diploma or some 
vocational school (1222)
High school diploma, general 
equivalence diploma or some 
vocational school (1788)
for high school graduates (497)
Education Level 3 (N) 1-4 years of college (487) 1-4 years of college (2558) 1-4 years of college (953) 1-4 years of college (587) some college (777)









Some graduate/ professional 
school (303)
N/A
Income Level 1 (N) N/A Under $5000 (98) Under $5000 (92) N/A for those reporting less than 10k (61)
Income Level 2 (N) N/A $5000-$7999 (118) $5000-$7999 (216) N/A for 10k to 25k (463)
Income Level 3 (N) N/A $8000-$11999 (261) $8000-$11999 (340) N/A for >25k up to <50k (581)
Income Level 4 (N) N/A $12000-$15999 (389) $12000-$15999 (489) N/A for 50K+ (343)
Income Level 5 (N) N/A $16000-$24999 (1027) $16000-$24999 (657) N/A N/A
Income Level 6 (N) N/A $25000-$34999 (1541) $25000-$34999 (539) N/A N/A
Income Level 7 (N) N/A $35000-$49999 (1831) $35000-$49999 (365) N/A N/A
Income Level 8 (N) N/A Over $50000 (2578) Over $50000 (492) N/A N/A
Linear Heterozygosity Whole Genome - Mean 0.9969 0.9989 0.9945 0.9973 0.9953
Linear Heterozygosity Whole Genome - SD 0.0145 0.0096 0.0116 0.0096 0.0127
Linear Heterozygosity Whole Genome - Max 
Number of SNPs Used
231171 371011 327843 211955 711732
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HRS INCHIANTI LBC1921 LBC1936 MAP ROS Rotterdam
8617 1012 418 859 710 788 4903
1089 381 307 97 321 458 2751
58.22% 55.14% 56.22% 47.85% 72.41% 65.68% 59.36%
29.13 27.18 26.16 27.83 26.89 27.12 26.30
4.64 11.36 5.12 2.98 6.09 9.69 13.22
79.88 85.17 87.12 72.62 89.06 87.41 73.67
2006-2008 1998-2000 1999-2001 2004-2007 1997-2008 1994-2008 1990-1993
2006-2008 1998-2000 1999-2001 2004-2007 1997-2008 1994-2008 1990-1993
Illumina Human Omni2.5-4v1 Illumina 550K Illumina 610 quad v1 Illumina 610 quad v1 Affymetrix 6.0 Affymetrix 6.0 Illumina 550K 
GenomeStudio version 2011.2, 
Genotyping Module 1.9.4 and 
GenTrain version 1.0
Birdseed Illumina GenomeStudio Illumina GenomeStudio Birdsuite, Broad Institute Birdsuite, Broad Institute The Beadstudio  
PLINK, R and SAS PLINK, R, SAS PLINK and R PLINK and R PLINK and R PLINK and R PLINK and R
<12th grade (1117) <6th grade (692) <11th grade (285) <11th grade (627) <11th grade (50) <11th grade (18) <11th grade (1409)
High school diploma, general 
equivalence diploma (4935)
6-12 years (179) High school diploma, 
general equivalence 
diploma or some 
vocational school (50)
High school diploma, 
general equivalence 
diploma or some 
vocational school (133)
High school diploma, 
general equivalence 
diploma or some 
vocational school (227)
High school diploma, general 
equivalence diploma or some 
vocational school (38)
High school diploma, 
general equivalence diploma 
or some vocational school 
(2555)
2yr college or 4yr college (1713) 12-16 years (98) 1-4 years of college (50) 1-4 years of college (48) 1-4 years of college (213) 1-4 years of college (42) 1-4 years of college (1361)












Under $5000 (80) N/A N/A N/A Under $5000 (15) N/A min-$23000 (760)
$5000-$7999 (106) N/A N/A N/A $5000-$9999 (29) N/A >$23000-$32000 (840)
$8000-$11999 (378) N/A N/A N/A $10000-$14999 (48) N/A >$32000-$40000 (869)
$12000-$15999 (481) N/A N/A N/A $15000-$19999 (78) N/A >$40000-$52000 (912)
$16000-$24999 (1017) N/A N/A N/A $20000-$24999 (69) N/A >$52000-$70000 (1092)
$25000-$34999 (1238) N/A N/A N/A $25000-$34999 (135) N/A >$70000 (478)
$35000-$49999 (1373) N/A N/A N/A $35000-$49999 (145) N/A N/A
Over $50000 (3944) N/A N/A N/A Over $50000 (222) N/A N/A
0.9987 0.9989 0.9991 1.0023 1.000 0.999 0.9980
0.0086 0.0064 0.0087 0.0065 0.009 0.008 0.0070
840464 384883 410009 404427 297689 297689 433844
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SHIP ARIC - African HealthABC - African HRS - African CHS - African
3311 2473 995 1513 771
424 825 584 220 562
44.85% 62.38% 55.58% 63.85% 62.13%
27.19 29.77 28.49 31.14 N/A
11.23 18.58 10.10 4.52 11.95
74.00 71.98 81.89 75.90 83.98
1997-2001 1987-1989 1997-1998 2006-2008 1989-1990
1997-2001 1987-1998 1997-1998 2006-2008 1989-1990




Birdseed2 Birdseed GenomeStudio GenomeStudio version 
2011.2, Genotyping Module 
1.9.4 and GenTrain version 
1.0
GenomeStudio
PLINK and R PLINK and R PLINK and R PLINK, R and SAS PLINK and R
<=8 years of school (1267) <11th grade (1028) for those reporting grade 11 or less, also for those 
reporting vocation/trade school without GED 
(437)
<12th grade (534) <11th grade (336)
10 years of school (1475) High school diploma, general 
equivalence diploma or some 
vocational school (736)
for high school graduates (301) High school diploma, general 
equivalence diploma (730)
High school diploma, general 
equivalence diploma or some 
vocational school (210)
>10 years of school (569) 1-4 years of college (465) some college (257) 2yr college or 4yr college 
(174)
1-4 years of college (142)
N/A Some graduate/professional school 
(370)
N/A Master's degree or Ph.D. (75) Some graduate/professional 
school (83)
under 1375 €/month (582) Under $5000 (340) for those reporting less than 10k (264) Under $5000 (61) Under $5000 (112)
- 1875 €/month (400) $5000-$7999 (243) for 10k to 25k (488) $5000-$7999 (111) $5000-$7999 (174)
- 2375 €/month (452) $8000-$11999 (302) for >25k up to <50k (191) $8000-$11999 (210) $8000-$11999 (113)
- 2875 €/month (491) $12000-$15999 (268) for 50K+ (52) $12000-$15999 (169) $12000-$15999 (111)
- 3250 €/month (366) $16000-$24999 (446) N/A $16000-$24999 (242) $16000-$24999 (100)
- 3750 €/month (290) $25000-$34999 (305) N/A $25000-$34999 (198) $25000-$34999 (84)
- 4750 €/month (428) $35000-$49999 (242) N/A $35000-$49999 (167) $35000-$49999 (45)
over 4750 €/month (302) Over $50000 (176) N/A Over $50000 (355) Over $50000 (32)
0.9991 0.9986 0.9968 0.9984 0.9958
0.0089 0.0156 0.0202 0.0120 0.0278
389567 386600 757443 919711 654600
16
2.6 Figures
Figure 2.1: Heterozygosity Meta-Analysis by Study
1.57% decreased risk of death for every standard deviation increase in 
heterozygosity. This is determined using an inverse variance weighted 
fixed effect model. Significance of P=0.03 is determined using Stouffer's 
method to combine Z-scores due to bias in inverse variance weighted 
fixed effect model. There are 46,716 individuals, including a total of 
15,234 deaths and an average age at death of 80 years old. EA = 
European Ancestry; AA = African Ancestry; AGES = Age, 
Gene/Environment Susceptibility cohort; ARIC = Atherosclerosis Risk In 
Communities cohort; CHS = Cardiovascular Health Study; FHS = 
Framingham Heart Study; HealthABC = HealthABC cohort; HRS = Health 
and Retirement Study; INCHINTI = InCHIANTI cohort; LBC1921 = 1921 
Lothian Birth Cohort; LBC1936 = 1936 Lothian Birth Cohort; MAP = 
Rush Memory and Aging Project cohort; ROS = Religious Orders Study; 
Rotterdam = Rotterdam Study; SHIP = Study of Health In Pomerania 
cohort; SE = Standard Error; HR = Hazard Ratio; CI = Confidence 
Interval; W = Weight; N = Number
17
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Figure 2.2: Ancestry Meta-Analysis
Direct comparison of European Ancestry to African ancestry cohorts 




Figure 2.3: Chromosome Meta-Analysis
A meta-analysis for each chromosome was performed across studies. No 
significant difference was observed between effects across chromosomes 
(P=0.17). Figure is formatted the same as Figure 2.1.
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Figure 2.4: Causes of Death Meta-Analysis
A meta-analysis for each cause of death was performed. Our results 
show no significant evidence for heterogeneity (P=0.79). Figure is 
formatted the same as Figure 2.1.
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Figure 2.5: Sex Meta-Analysis
A meta-analysis was performed separately for each sex. Our results do 
not provide evidence for a differential effect of heterozygosity on survival 
in men vs. women (P=0.49). Figure is formatted the same as Figure 2.1.
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Figure 2.6: Heterozygosity Determined Using Various SNP Lists
Also included as a supplement is a figure showing the relationship 
between heterozygosity metrics determined using different SNP lists. The 
dataset used was genome wide SNP data from sequencing of 503 
individuals with European ancestry from 1000G phase 3 release. The 
SNP lists used were: 1) all SNPs 2) SNPs on the Illumina 1M 3) SNPs on 
the Illumina 610quad 4) SNPs on the Illumina Omni2.5 and 5) SNPs on 
the Affymetrix 6.0. This is to determine if SNP selection on the arrays 




2.7 Methods – Heterozygosity
Self-described Caucasian ("white", "Caucasian") and African 
ancestry ("black", "African American") individuals were included after 
excluding first and second-degree relatives and genetic outliers. Genetic 
outliers were defined by merging genotyping data with HapMap3 data, 
and calculating the Euclidean distance from a combined reference 
HapMap3 population (Caucasian=CEU+TSI, African 
ancestry=ASW+YRI+MKK+LWK) cluster centroid in the first 3 PC space 
weighted by explained variance. Specifically, the standard deviation of 
Euclidean distance was determined for each HapMap reference group, 
and any sample greater than ten standard deviations away from centroid 
were defined as genetic outliers and excluded.
Directly genotyped SNPs were used for all analyses. Imputed SNPs 
were not used to avoid issues with genotype accuracy and bias towards 
the reference panel. SNP exclusion criteria included: monomorphic in the 
dataset, non-unique mapping to Hg19, SNPs which are no longer in the 
company provided annotation file for the SNP array, >0.5% missing data, 
MAF ≤ 10%, HWE p-value ≥ 0.001, and non-autosomal SNPs. The 
heterozygosity metric is the sum of all heterozygous loci divided by the 
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 where p is the frequency of the major allele.
Separate association analyses were run for Caucasian and African 
ancestry samples from each cohort. The CoxPH model included 
covariates for Body Mass Index (BMI) at first visit and first ten principal 
components, and the 'strata' function for sex, education level (defined as 
1. ≤11th grade, 2. high school diploma, general equivalence diploma or 
some vocational school, 3. 1–4 years of college, 4. Some 
graduate/professional school, and Missing), income level (defined by 
cohorts), and center of DNA collection within cohorts. The CoxPH model 
was set up so that the outcome was age at study entry, age at study exit, 
and a binary variable coding state of death (1: Dead, 0: Alive). Age is 
measured in units of years, but is accurate to the nearest day.
For the meta-analysis, significance was determined by Stouffer's 
method (Stouffer Samuel et al.) calculated as a two-sided test by 
incorporating Z-scores derived from two-sided tests performed in each 
cohort. We standardized the beta estimates by multiplying them by the 
standard deviation of the heterozygosity metric for each cohort, to 
account for the fact that the effect size is proportional to the variance in 
the heterozygosity metric. The variance heterozygosity metric in turn is 
proportional to the inverse of the square root of the number of SNPs used 
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to determine the heterozygosity metric. Because most cohorts used 
different genotyping arrays, a large bias is introduced into the meta-
analysis. Stouffer’s method completely removes this bias; however, 
cannot estimate a combined effect size, only the overall significance. To 
get an estimate of the combined effect size (recognizing that the P-value 
and associated confidence intervals will be inflated), we used inverse 
variance weighting of the standardized cohort effect sizes, which partially 
corrects the bias and allows for the combined effect size to be estimated.
2.8 Methods – Cohorts
ARIC
The Atherosclerosis Risk In Communities (ARIC) study was established 
in 1986 as a prospective study of 15,792 individuals, 45-65 years of age, 
from 4 different US communities (Jackson, Mississippi; Forsyth County, 
North Carolina; Washington County, Maryland; suburbs of Minneapolis, 
Minnesota). The first visit was carried out in 1987-89, with four 
subsequent in-person visits and annual telephone interviews after initial 
visit. Mortality was tracked via telephone follow-ups, hospitalization 
records, state records, and the National Death Index. Each visit 
consisted of data collected about electrocardiographic measures and 
cardiovascular outcomes. Cause of death was determined using cause of 
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death on the death certificate (ICD code). Only samples with a self-
reported race of white or black were included in this analysis (“The 
Atherosclerosis Risk in Communities (ARIC) Study”). 
AGES
The Age, Gene/Environment Susceptibility (AGES Reykjavik) Study 
(Tamara B Harris et al., “Age, Gene/Environment Susceptibility-
Reykjavik Study”) was initiated to examine genetic susceptibility and 
gene/environment interaction as these contribute to phenotypes 
common in old age. The Reykjavik Study cohort originally comprised a 
random sample of 30,795 men and women born in 1907-1935 and living 
in Reykjavik in 1967. A total of 19,381 people attended, resulting in 71% 
recruitment rate. The study sample was divided into six groups by birth 
year and birth date within month. One group was designated for 
longitudinal follow up and was examined in all stages. One group was 
designated a control group and was not included in examinations until 
1991. Other groups were invited to participate in specific stages of the 
study. Between 2002 and 2006, the AGES-Reykjavik study re-examined 
5764 survivors of the original cohort who had participated before in the 
Reykjavik Study. Successful genotyping was available for 3219 AGES 
participants who were eligible for this study. The AGES Reykjavik Study 
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GWAS was approved by the National Bioethics Committee and the Data 
Protection Authority.
CHS
The Cardiovascular Health Study (CHS) (Fried et al.) is a population-
based cohort study of risk factors for CHD and stroke in adults ≥65 years 
conducted across four field centers. The original predominantly 
Caucasian cohort of 5,201 persons was recruited in 1989-1990 from 
random samples of the Medicare eligibility lists; subsequently, an 
additional predominantly African-American cohort of 687 persons were 
enrolled for a total sample of 5,888. DNA was extracted from blood 
samples drawn on all participants at their baseline examination in 1989-
90. In 2007-2008, genotyping on the European ancestry individuals was 
performed at the General Clinical Research Center's 
Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 
370CNV BeadChip system on the CHS participants who were free of CVD 
at baseline, consented to genetic testing, and had DNA available for 
genotyping. In 2010, genotyping on the African-American CHS 
participants who consented to genetic testing, and had DNA available for 
genotyping was performed at the General Clinical Research Center's 




The Framingham Heart Study (DAWBER, MEADORS, and MOORE; 
Feinleib et al.; Kannel et al.; Splansky et al.) is a community-based 
family study initiated to study determinants of cardiovascular and other 
chronic diseases. The study started in 1948 with the enrollment of 5,209 
men and women who have been examined every two years since study 
inception. In 1971, 5,124 children of the original cohort and spouses of 
the children were enrolled in the Offspring cohort and have been 
examined every 4 to 8 years. Beginning in 2002, 4,095 adult 
grandchildren of the original cohort (children of the Offspring cohort) 
were enrolled into the Third Generation cohort (Gen 3) and have 
completed two examinations. Blood samples for DNA collection were 
obtained on the surviving original cohort and Offspring members in the 
1990s and on the Gen 3 participants on study entry. Participants from 
all three cohorts are under continuous surveillance for death. For the 
purposes of this genetic heterozygosity investigation, Original cohort and 
Offspring participants were followed from the time of DNA draw until 
death or end of follow –up in 2009. There were 4525 participants (2485 
women) included in the study sample and 1332 deaths (664 deaths in 
women, mean age at death 81.7 years) occurred during follow-up (mean 
follow –up time 9.1 years). CoxPH models were used to determine the 
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linear effect of heterozygosity on survival. A robust variance estimate 
clustering on family was used to account for family correlation. 
Additional models examined the association of quintiles of heterozygosity 
with survival. As described in the analysis section, the models were 
adjusted for body mass index at baseline and principal components 1-
10, stratified by sex and education category. In secondary analyses, sex 
specific models and by-chromosome heterozygosity were examined. 
Income at baseline was not available and therefore not included in the 
model.
HealthABC
HealthABC (Tamara B. Harris et al.). Genomic DNA was extracted from 
buffy coat collected using PUREGENE® DNA Purification Kit during the 
baseline exam. In 2009, genotyping was performed by the Center for 
Inherited Disease Research (CIDR) using the Illumina Human1M-Duo 
BeadChip system. Samples were excluded from the dataset for the 
reasons of sample failure (call rate < 95%), genotypic sex mismatch, and 
first-degree relative of an included individual based on genotype data. 
African American and European ancestry were confirmed using principal 
components analyses with HapMap 3 populations as references. 
Genotyping was successful in 2,802 individuals (1663 European 
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ancestry and 1139 African Americans). Genotypes were available on 
914263 high quality SNPs.
HRS
The Health and Retirement Study (HRS) (Juster and Suzman) is a 
longitudinal survey of a representative sample of Americans over the age 
of 50. The current sample is over 26,000 persons in 17,000 households. 
The study interviews respondents every two years about income and 
wealth, health and use of health services, work and retirement, and 
family connections. DNA was extracted from saliva collected during a 
face-to-face interview in the respondents' homes. These data represent 
respondents who provided DNA samples and signed consent forms in 
2006 and 2008.
InCHIANTI
The InCHIANTI study (Ferrucci et al.) is a population-based 
epidemiological study aimed at evaluating the factors that influence 
mobility in the older population living in the Chianti region in Tuscany, 
Italy. The details of the study have been previously reported. Briefly, 
1616 residents were selected from the population registry of Greve in 
Chianti (a rural area: 11,709 residents with 19.3% of the population 
greater than 65 years of age), and Bagno a Ripoli (Antella village near 
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Florence; 4,704 inhabitants, with 20.3% greater than 65 years of age). 
The participation rate was 90% (n=1453), and the subjects ranged 
between 21-102 years of age. Illumina Infinium HumanHap 550K SNP 
arrays were used for genotyping. The study protocol was approved by the 
Italian National Institute of Research and Care of Aging Institutional 
Review and Medstar Research Institute (Baltimore, MD).
LBC
Lothian Birth Cohorts 1921 and 1936 (LBC1921, LBC1936) (Deary, 
Whiteman, et al.; Deary, Gow, Taylor, et al.; Deary, Gow, Pattie, et al.)
The Lothian Birth Cohort 1936 (LBC1936) consists of 1,091 relatively 
healthy individuals assessed on cognitive and medical traits at about 70 
years of age. They were born in 1936, most took part in the Scottish 
Mental Survey of 1947, and almost all lived independently in the Lothian 
region of Scotland in older age. At recruitment the sample of 548 men 
and 543 women had a mean age 69.6 years (SD = 0.8). Two further 
waves were carried out at 73 (n = 866 (448 males, 418 females) and 76 
years of age (in progress). A full description of participant recruitment 
and testing can be found elsewhere. At recruitment the LBC1921 cohort 
consisted of 550 relatively healthy individuals, 316 females and 234 
males, assessed on cognitive and medical traits at about 79 years of age. 
Three further testing waves were completed at 83 (n = 321 (145 males, 
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176 females), 87 (n = 235 (109 males, 126 females) and 90 (n = 129 (59 
males, 70 females) years of age. They were all born in 1921, most took 
part in the Scottish Mental Survey of 1932, and almost all lived 
independently in the Lothian region (Edinburgh City and surrounding 
area) in Scotland in older age. When tested, the sample had a mean age 
of 79.1 years (SD = 0.6). A full description of participant recruitment and 
testing can be found elsewhere. Ethics permission for the study was 
obtained from the Multi-Centre Research Ethics Committee for Scotland 
(MREC/01/0/56) and from Lothian Research Ethics Committee 
(LBC1936: LREC/2003/2/29 and LBC1921: LREC/1998/4/183). The 
research was carried out in compliance with the Helsinki Declaration. All 
subjects gave written, informed consent.
MAP/ROS
Religious Orders Study (ROS) (Bennett, Schneider, Arvanitakis, et al.)
The ROS, started in 1994, is a longitudinal, clinical-pathologic cohort 
study of common chronic conditions of aging. The study enrolls Catholic 
priests, nuns, and brothers from about 40 groups in 12 states of the 
United States. Since January 1994, over 1,100 participants completed 
their baseline evaluation. The study was approved by the institutional 
review board of Rush University Medical Center. The follow-up rate of 
survivors exceeds 90%. Participants were free of known dementia at 
38
enrollment, agreed to annual clinical evaluations, and signed both an 
informed consent and an Anatomic Gift Act form donating their brains at 
time of death. DNA was extracted from whole blood, lymphocytes, or 
frozen postmortem brain tissue. Genotyping was performed at the Broad 
Institute’s Center for Genotyping and the Translational Genomics 
Research Institute.
Rush Memory and Aging Project (MAP) (Bennett, Schneider, Buchman, et 
al.)
The MAP, started in 1997, is a longitudinal, clinical-pathologic cohort 
study of common chronic conditions of aging. The study enrolled older 
men and women from assisted living facilities in the Chicago area with 
no evidence on dementia at baseline. Since October 1997, over 1,500 
participants completed their baseline evaluation. The study was 
approved by the institutional review board of Rush University Medical 
Center. The follow-up rate of survivors exceeds 90%. Similar to the ROS, 
participants agreed to annual clinical evaluations and signed both an 
informed consent and an Anatomic Gift Act form donating their brains, 
spinal cords, and selected nerves and muscles to Rush investigators at 
the time of death. DNA was extracted from whole blood, lymphocytes, or 
frozen postmortem brain tissue. Genotyping was performed at the Broad 




The Rotterdam Study (Hofman, Breteler, et al.) is a prospective cohort 
study ongoing since 1990 in the city of Rotterdam in The Netherlands. 
The study targets cardiovascular, endocrine, hepatic, neurological, 
ophthalmic, psychiatric, dermatological, oncological, and respiratory 
diseases. As of 2008, 14,926 subjects aged 45 years or over comprise the 
Rotterdam Study cohort. The findings of the Rotterdam Study have been 
presented in over a 1,000 research articles and reports (www.erasmus-
epidemiology.nl/rotterdamstudy).
SHIP
The Study of Health in Pomerania (SHIP) (John et al.; Völzke et al.) is a 
cross-sectional survey in West Pomerania, the north-east area of 
Germany. A sample from the population aged 20 to 79 years was drawn 
from population registries. First, the three cities of the region (with 
17,076 to 65,977 inhabitants) and the 12 towns (with 1,516 to 3,044 
inhabitants) were selected, and then 17 out of 97 smaller towns (with 
less than 1,500 inhabitants), were drawn at random. Second, from each 
of the selected communities, subjects were drawn at random, 
proportional to the population size of each community and stratified by 
age and gender. Only individuals with German citizenship and main 
40
residency in the study area were included. Finally, 7,008 subjects were 
sampled, with 292 persons of each gender in each of the twelve five-year 
age strata. In order to minimize drop-outs by migration or death, 
subjects were selected in two waves. The net sample (without migrated or 
deceased persons) comprised 6,267 eligible subjects. Selected persons 
received a maximum of three written invitations. In case of non-
response, letters were followed by a phone call or by home visits if 
contact by phone was not possible. The SHIP population finally 
comprised 4,308 participants (corresponding to a final response of 
68.8%). Genotyping: The SHIP samples were genotyped using the 
Affymetrix Genome-Wide Human SNP Array 6.0. Hybridisation of 
genomic DNA was done in accordance with the manufacturer’s standard 
recommendations. The genetic data analysis workflow was created using 
the Software InforSense. Genetic data were stored using the database 
Caché (InterSystems). Genotypes were determined using the Birdseed2 
clustering algorithm. For quality control purposes, several control 
samples where added. On the chip level, only subjects with a genotyping 
rate on QC probesets (QC callrate) of at least 86% were included. Finally, 
all arrays had a sample callrate > 92%. The overall genotyping efficiency 
of the GWA was 98.55%. Duplicate samples as estimated by IBD and 




Institutional Review Board approvals were obtained by each 
participating ARIC study center (the Universities of NC, MS, MN, and 
John Hopkins University) and the coordinating center (University of NC), 
and the research was conducted in accordance with the principles 
described in the Helsinki Declaration. All subjects in the ARIC study gave 
informed consent. For more information see dbGaP Study Accession: 
phs000280.v2.p1. JHSPH IRB number H.34.99.07.02.A1. Manuscript 
proposal number MS1964.
HealthABC Human subjects protocol UCSF IRB is H5254-12688-
11.
CHS was approved by institutional review committees at each site, 
the subjects gave informed consent, and those included in the present 
analysis consented to the use of their genetic information for the study of 
cardiovascular disease. It is the position of the UW IRB that these 
studies of de-identified data, with no patient contact, do not constitute 
human subjects research. Therefore we have neither an approval 
number, nor an exemption.
IRB permission to conduct genetics-related work in the Health and 
Retirement Study (HRS) is granted under the project title, "Expanding a 
National Resource for Genetic Research in Behavioral & Health Science" 
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(HUM00063444). The IRB that approved this project is the Health 
Sciences and Behavioral Sciences Institutional Review Board at the 
University of Michigan. No manuscript proposal is required for use of 
HRS data.
Inchianti ethics review statement: The study protocol was approved 
by the Italian National Institute of Research and Care of Aging 
Institutional Review and Medstar Research Institute (Baltimore, MD).
The Religious Orders Study (ORA# 91020181) and the Rush 
Memory and Aging Project (ORA# 86121802) were approved by the 
Institutional Review Board of Rush University Medical Center. Written 
informed consent was obtained from all the participants.
The SHIP study followed the recommendations of the Declaration 
of Helsinki. The study protocol of SHIP was approved by the medical 
ethics committee of the University of Greifswald. Written informed 
consent was obtained from each of the study participants. The SHIP 
study is described in PMID: 20167617
The Rotterdam Study has been approved by the medical ethics 
committee according to the Population Study Act Rotterdam Study, 
executed by the Ministry of Health, Welfare and Sports of the 
Netherlands. A written informed consent was obtained from all 
participants.
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The Boston University Medical Campus Institutional Review Board 
approved the FHS genome-wide genotyping (protocol number H-226671) 
and genetic investigation of aging and longevity phenotypes (protocol 
number H-24912).
The Age, Gene/Environment Susceptibility Reykjavik Study has 
been funded by NIH contract N01-AG-12100, the NIA Intramural 
Research Program, Hjartavernd (the Icelandic Heart Association), and the 
Althingi (the Icelandic Parliament). The study is approved by the 
Icelandic National Bioethics Committee, (VSN: 00-063) and the Data 
Protection Authority. The researchers are indebted to the participants for 
their willingness to participate in the study.
Ethics permission for the LBC studies was obtained from the 
Multi-Centre Research Ethics Committee for Scotland (MREC/01/0/56) 
and from Lothian Research Ethics Committee (LBC1936: 
LREC/2003/2/29 and LBC1921: LREC/1998/4/183). The research was 




Chapter 3: ExomeChip and QT interval
3.1 Abstract
QT interval, measured through a standard EKG, captures the time 
it takes for the ventricles in the heart to depolarize and repolarize. JT 
interval, a measure of ventricular repolarization time alone, can be 
mathematically derived by subtracting the QRS interval, a measure of 
ventricular depolarization time, from the QT interval. Prolonged QT 
interval has been linked to higher risk of SCD. We performed an exome-
wide analysis for both QT and JT intervals, including both common and 
rare variants from the Illumina Infinium HumanExome BeadChip using 
single variant statistical models.
We performed a meta-analysis of 241,552 variants in 17,574 genes 
in a sample of 95,626 individuals from 23 cohorts (comprised of 83,884 
European ancestry individuals, 9,610 African Americans, 1,382 
Hispanics, and 750 Asian individuals) and identified 10 loci that 
modulate QT interval and/or JT interval that have not been previously 
reported in the literature. This brings the total number of ventricular 
repolarization time associated loci to 45. Additionally, our approach of 
using coding variants has highlighted the role of 17 specific genes in 
ventricular repolarization time regulation, 7 of which are in novel loci.
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3.2 Author Summary
We investigate the genetic effect coding variants have on 
ventricular repolarization time and in doing so implicate 17 specific 
genes as regulating repolarization time. Our analyses show a role for the 
internal structure of myocytes and interconnection of myocytes in 
modulating QT interval duration, adding to previous known roles of 
potassium ion regulation, sodium ion regulation, calcium ion regulation, 
and autonomic control. We anticipate these discoveries will open new 
paths to the goal of making novel remedies for the prevention of lethal 
ventricular arrhythmias and SCD.
3.3 Introduction
QT interval, determined via a standard non-invasive EKG, is a 
classic measure of ventricular repolarization time. Prolonged QT interval 
has been linked to higher risk of SCD, with between 180,000 and 
450,000 cases of SCD in the United States of America annually (Deo and 
Albert). Since the vast majority of SCD occurs in the absence of clinical 
features that would bring a victim to medical attention (Chugh et al.), 
identifying additional risk factors and dissecting the etiology of disease is 
of high importance.
Heritability estimates of QT interval are between 30 and 40%, 
indicating that genetic variants play a large role in modulating QT 
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interval in the general population (Newton-Cheh, Larson, et al. 3). In 
addition, Mendelian syndromes of QT interval (Long QT Syndrome [LQTS] 
and Short QT Syndrome [SQTS]) occur in ~1:2000 individuals, and are 
caused by variants in ion channels or their interacting proteins 
(Schwartz, Crotti, and Insolia).
Previous candidate gene and genome-wide association studies (GWAS), 
largely screening common non-coding variants, have identified 35 loci 
containing variants of small effect (Pfeufer et al.; Newton-Cheh, 
Eijgelsheim, et al.; Arking, Pfeufer, et al. 1; Nolte et al.; Holm et al.; 
Noseworthy et al.; Kim et al.; Arking, Pulit, et al.), with the largest study, 
QTIGC (Arking, Pulit, et al.), including a discovery population of 76,061 
European ancestry individuals. Together, familial and population-based 
studies of QT interval have highlighted prominent roles for potassium ion 
regulation via observed associated variation in KCNQ1 (LQT1, SQT2), 
KCNH2 (LQT2, SQT1), KCNJ2 (LQT7, SQT3), and KCNE1 (LQT5), sodium 
ion regulation via observed associated variation in SCN5A (LQT3), CAV3 
(LQT9), and SNTA1 (LQT10), and calcium ion regulation via observed 
associated variation in CACNA1C (LQT8), ATP2A2, PLN, PRKCA, SRL, and 
SLC8A1.
In this study, we conduct exome-wide analyses in population-
based samples to interrogate the role of a largely unstudied class of 
variation on ventricular repolarization time in the population – coding 
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variants. These variants fill in the gap between the extremely rare large-
effect coding variants that result in the Mendelian L/SQT syndromes and 
the common small-effect largely non-coding variation identified through 
GWAS. The focus on exons and coding variants has an added benefit, in 
that genes are directly implicated, whereas non-coding variation typically 
only implicates a region of the genome, often containing multiple genes, 
requiring extensive functional experiments to directly implicate a gene. 
Despite extensive bioinformatics analyses, QTIGC only narrowed down 
the list of candidate genes to 48 in 25 loci, with no clear candidates in 
the remaining 10 loci. Our study, with its focus on coding variation, 
facilitates a direct link between gene and phenotype.
We performed a meta-analysis of 23 cohorts, including 95,626 
multi-ethic individuals comprised of 83,884 European ancestry 
individuals, 9,610 African Americans, 1,382 Hispanics, and 750 Asian 
individuals (Table 3.3). Each individual was genotyped for 241,552 
variants in 17,574 genes using the Illumina Infinium HumanExome 
BeadChip (ExomeChip). These variants were chosen by evaluating 
approximately 12,000 exome sequences for coding variants that 
appeared in at least two individuals along with non-coding variants of 
known importance from previous GWAS and variants tiling across the 
genome. Organizing of the sequencing, genotyping, and phenotyping was 
done as a part of the Cohorts for Heart and Aging Research in Genomic 
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Epidemiology (CHARGE) Consortium (Psaty et al.) EKG and ExomeChip 
working groups.
3.4 Results
6 Novel Loci Associated with QT Interval
Single nucleotide variants (SNVs) in 25 loci were associated with 
QT interval at exome-wide significance. Of these, 19 loci were previously 
identified and 6 loci were novel. All 41 QT interval known and novel 
associated loci are shown in Table 3.1, with the most significant SNV 
from the current analyses shown. The 6 novel loci are listed by nearest 
gene, and for four of these loci (PM20D1, SLC4A3, CASR, NRAP), the top 
hit is a nonsynonymous variant, providing direct evidence that the gene 
is involved in modulating QT interval.
Utilization of Coding Variants to Implicate Genes
For genes in the 35 previously identified loci for which the top SNV 
in our study is putative functional coding variant (14 loci), we wanted to 
determine whether the associated variant implicates a causal gene, or 
alternatively, is associated due to linkage disequilibrium with a more 
strongly associated non-coding variant, and thus would not provide 
evidence for the gene being involved in modulating QT interval. We 
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therefore determined the correlation between the top SNV in the current 
study, and the previously reported most significant SNV from QTIGC in 
ARIC European ancestry individuals (Table 3.4). We saw moderate-to-
high LD (r2>0.5) in 5 of the 14 loci. We then performed conditional 
analyses by including both variants in the same regression model in the 
same ARIC Europeans dataset (Table 3.4). Conditional analyses 
demonstrate that the TTN coding variant explains the common variant 
association initially reported by QTIGC. For four additional loci, the 
nonsynonymous coding variant is independent of the QTIGC signal, 
supporting a specific gene within the locus: SP3, SPATS2L, MATN2 at the 
“LAPTM4B” locus, and DCAF13 at the “AZ1N1” locus. Although the 
coding variants in those last four genes are not exome-wide significant. 
(Locus names are taken from previously published studies on QT 
interval; namely QTIGC (Arking, Pulit, et al.).)
As we have noted previously (Arking, Pulit, et al.), several loci 
contain multiple independent genetic effects, including some loci 
harboring multiple exome-wide significant coding variants (Table 3.5). 
Thus, even if not the top hit at a locus, putative functional SNVs can still 
implicate a specific gene at a locus. We used the Gene-Wide Significance 
(GWiS) (Huang et al.) software to determine the number of independent 
effects in all loci along with a SNV that best represents each independent 
effect (Table 3.6). The SCN5A-SCN10A locus is a particularly illustrative 
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example of the utility of this approach. Coding variants in DLEC1, 
SCN5A, and SCN10A are each exome-wide significant (Table 3.2). 
However, after utilizing GWiS, the signal coming from the coding variants 
in DLEC1 and SCN5A is explained by non-coding variants and only the 
SCN10A coding variant signal remains. Included in Table 3.1 is each 
gene that GWiS has found an independent effect represented by a coding 
variant.
JT Interval GWAS Identifies 4 Novel Loci
There have been previous reports where SNVs effect QT interval 
and QRS interval, a measure of ventricular depolarization time, in 
opposite directions (Arking, Pulit, et al.; Sotoodehnia et al.). While 
ventricular depolarization time and repolarization time are often co-
regulated, the difference in genetic effect indicates this is not universally 
true. By looking at only ventricular repolarization time, we should have 
increased statistical power to detect variants that specifically effect 
ventricular repolarization time and thus detect additional loci while 
teasing apart the differential regulation of the various phases of 
ventricular conduction. Ventricular repolarization time begins at the Q 
point of an EKG; however ventricular depolarization time does not finish 
until the S point of an EKG. Therefore, the time that both processes are 
co-occurring is included in the QT interval. We define JT interval 
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mathematically as subtracting the QRS interval from the QT interval in 
milliseconds. In ARIC’s 15,590 participants, the correlation between QT 
and JT is 0.92. We analyzed JT interval the same way as QT interval 
described above, while adding QRS interval as an additional covariate to 
further remove the effect of ventricular depolarization time on the 
analysis. Four loci that were not observed as QT loci achieved exome-
wide significance, including three loci harboring significant coding 
variants: SENP2, SLC12A7, and NACA.
in silico Analyses
To further decode the role these new loci might play in regulating 
ventricular repolarization time, Data-driven Expression-Prioritized 
Integration for Complex Traits (DEPICT) (Pers et al.) was used to 
investigate if identified loci contain genes from functional annotated gene 
sets/pathways. The 45 SNVs from Table 3.1 were used to seed the 
algorithm, only 38 SNVs were able to be used by the algorithm. Included 
in Table 3.1 is a list of genes with FDR<5%. Three gene sets passed the 
false discovery rate (FDR) cutoff of 5%: C1QA subnetwork 
(ENSG00000173372; p=1.97E-6), fascia adherens (GO:0005916; 
p=8.28E-6), and ACOT13 subnetwork (ENSG00000112304; p=9.02E-6). 
Three tissues also passed the FDR cutoff of 5%: Heart Ventricles 
53
(A07.541.560; p=9.56E-4), Heart (A07.541; p=9.74E-4), and Atrial 
Appendage (A07.541.358.100; p=0.00283).
We also looked up each of the Table 3.1 representative SNVs and 
GWiS independent SNVs in the GTEx Portal to identify single-tissue 
expression quantitative trait loci (eQTL). The results are presented in 
Table 3.1 (left ventricle association noted in bold). Interestingly, 
rs1361754 was found to be both an exome-wide significant coding 
variant in PM20D1 and an eQTL for the same gene in left ventricle. 
Similarly, rs1805123 in KCNH2 and rs1042391 in GMPR, are both 
nonsynonymous variants as well as eQTLs, though not in left ventricle.
3.5 Discussion
Our approach of focusing on coding variants has identified 10 
novel loci associated with QT/JT interval, and highlighted the role of 17 
specific genes, 7 of which are from novel loci: PM20D1, SLC4A3, CASR, 
NRAP, SENP2, SLC12A7, and NACA. Not all 35 loci in the QTIGC study 
were replicated in our data despite the two studies have comparable 
discovery population sizes. This is likely due to the ExomeChip focusing 
on coding variation, with clear lack of coverage for some parts of the 
genome.
Previous studies have implicated roles for potassium ion 
regulation, sodium ion regulation, calcium ion regulation, and autonomic 
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control of QT interval (Porta et al.), and our results provide support for 
each of these pathways. SLC12A7 (KCC4), which GTEx shows is highly 
expressed in the left ventricle, is a potassium-chloride cotransporter 
involved in potassium efflux (Mount et al.). CASR is a G protein-coupled 
receptor that maintains circulating calcium ion homeostasis via PTH 
secretion in the parathyroid and kidney tubule ion handling (Hendy et 
al.).
Other genes do not fit into our current understanding of QT 
interval regulation. SLC4A3 (AE3), which GTEx shows is highly expressed 
in the heart and brain, has been found to be involved in anion exchange 
and cytoskeleton structural organization in neurons (Kopito et al.). 
SENP2, as a part of a nuclear pore complex, helps process SUMO1 (UBL1, 
ubiquitin-like protein) into its conjugatable form (Nishida et al.; Zhang, 
Saitoh, and Matunis). SENP2, which GTEx shows is highly expressed in 
the testis, brain and to a lesser extent ubiquitously, functional 
characterization in heart will be needed. Likewise, little is known about 
PM20D1 and functional characterization of this gene will be needed.
In addition to previously implicated pathways, our analyses 
highlight a role for the internal structure of myocytes and 
interconnection of myocytes in modulating QT interval duration, here 
after called mechanical control of QT interval. The GO category of fascia 
adherens (GO:0005916), identified by DEPICT, is comprised of the genes 
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that code for the structure that links myofibrils between cardiomyocytes 
and contains N-cadherin in the intercalated disc. The intercalated disc 
contains fascia adherens, desmosomes, and gap junctions, the last of 
which is known to play a role in ion-mediated relaying of action 
potentials between cardiomyocytes and, in combination with the gene 
NOS1AP, has been implicated as regulating QT interval (Kapoor et al.). 
We further implicate a non-ion dependent structural/mechanical 
interconnect via the fascia adherens. NRAP, found to have a significant 
independent coding variant, likely anchors terminal actin filaments of 
myofibrils to other protein complexes beneath the sarcolemma (Luo, 
Zhang, et al.; Luo, Leroy, et al.). Thus, NRAP, which GTEx shows is 
expressed exclusively in skeletal muscle and heart, likely plays a role in 
the mechanical control of QT interval. Likewise, skNAC, a muscle-specific 
isoform of NACA, which was found to have a significant independent 
coding variant, also likely affect mechanical control of QT interval. Most 
skNAC-specific knockout mice die between embryonic days 10.5 and 
12.5 due to cardiac defects, showing interventricular septal defects and a 
thin myocardial wall (Park et al.). With these three points of evidence 
combined with the previously known locus and GWiS-implicated gene, 
TTN, a clear class of genes mechanically effecting ventricular 
repolarization time emerges.
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In summary, we have identified 10 loci newly associated with 
ventricular repolarization time. This brings the total number of 
ventricular repolarization time associated loci to 45. Additionally, we 
have directly implicated 17 specific genes contained in these loci as likely 
affecting ventricular repolarization time and outlined a class of genes 
that mechanically control QT interval. These new discoveries will likely 
allow for the development of novel vectors for the prevention of lethal 
ventricular arrhythmias and SCD.
3.6 Tables
Table 3.1: Investigation of All Ventricular Repolarization Loci
Investigation of 35 previously known ventricular repolarization time loci 
presented by QTIGC and 10 novel loci from the current efforts. 
Representative SNVs are chosen to have the lowest p-value in each locus. 
Variant position information is from build GRCh37. Effect size estimates 
are in milliseconds (ms). However, p-values were determined from inverse 
rank normal transformed residuals to avoid p-value inflation from the 
analysis of rare variants. Loci are considered significantly associated if 
passing a Bonferroni correction, p-value < 2E-07. CAF = coded allele 
frequency. N = number of samples. SE = standard error. Discovery 
column indicates “QTIGC Validated” if a SNV was exome-wide significant 
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in this study, “QTIGC-only” if the locus could not be replicated, or 
“Novel” if the locus was first identified in this study. Within the QTIGC 
Implicated Gene(s) column, evidence for the gene is: c = coding variant, t 
= eQTL transcript, p = in silico protein-protein interactor, i = 
immunoprecipitation interactor. DEPICT genes pass FDR<5% cutoff. 
Expression quantitative trait loci (eQTL) genes are pulled from the GTEx 
portal using the representative SNV and GWiS independent SNVs. Gene 
is bold if the eQTL is in the left ventricle.
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Nearby Gene SNV Chr Pos
Coded/ 
Noncoded Allele CAF N
Effect in ms 
(SE) Pvalue
RNF207 rs709209 1 6,278,414 G/A 0.379 95,626 1.23 (0.09) 1E-48
TCEA3 rs1077514 1 23,766,233 G/A 0.179 92,753 -0.58 (0.11) 4E-08
NOS1AP rs12143842 1 162,033,890 T/C 0.240 95,626 3.18 (0.10) 3E-255
ATP1B1 rs10919071 1 169,099,483 G/A 0.115 95,626 -1.37 (0.13) 3E-30
SLC8A1 rs2540226 2 39,959,060 T/G 0.482 92,753 0.24 (0.08) 2E-03
SP3 rs1047640 2 174,820,750 C/T 0.120 95,626 0.60 (0.12) 3E-06
TTN-CCDC141 rs72648998 2 179,575,511 T/C 0.054 95,626 1.00 (0.18) 3E-09
SPATS2L rs192861441 2 201,303,848 A/G 0.004 95,626 -2.22 (0.67) 3E-04
SCN5A-SCN10A rs12053903 3 38,593,393 C/T 0.379 95,626 -0.88 (0.09) 1E-26
C3ORF75 rs2276853 3 47,282,303 G/A 0.411 95,626 -0.36 (0.08) 2E-05
SLC4A4 rs7689609 4 72,083,374 C/T 0.212 85,380 0.64 (0.12) 4E-08
SMARCAD1 rs7439869 4 95,173,779 T/C 0.378 95,626 0.41 (0.08) 8E-07
GFRA3 rs4835768 5 137,441,767 G/A 0.485 95,626 0.34 (0.08) 7E-05
GMPR rs1042391 6 16,290,761 T/A 0.551 89,579 -0.42 (0.09) 3E-06
SLC35F1-PLN rs11153730 6 118,667,522 C/T 0.467 95,626 1.41 (0.08) 5E-74
CAV1 rs3807989 7 116,186,241 A/G 0.429 95,626 0.54 (0.08) 4E-12
KCNH2 rs1805123 7 150,645,534 G/T 0.214 95,626 -1.47 (0.10) 7E-51
NCOA2 rs2926707 8 71,164,680 G/T 0.348 92,753 0.31 (0.09) 3E-04
LAPTM4B rs17831160 8 99,045,866 A/G 0.030 95,626 -0.64 (0.24) 3E-03
AZIN1 rs143025416 8 104,432,659 A/G 0.001 95,626 4.90 (1.55) 2E-03
GBF1 rs143226354 10 104,174,986 T/C 0.000 95,626 14.18 (4.66) 4E-03
KCNQ1 rs2074238 11 2,484,803 T/C 0.074 89,284 -3.58 (0.16) 8E-130
FEN1-FADS2 rs1535 11 61,597,972 G/A 0.325 95,626 -0.48 (0.09) 8E-10
ATP2A2 rs11068997 12 110,383,141 A/G 0.040 95,626 -0.94 (0.21) 4E-07
KLF12 rs1886512 13 74,520,186 A/T 0.381 80,552 0.57 (0.09) 2E-10
ANKRD9 rs11704 14 102,808,655 C/G 0.291 89,579 0.35 (0.09) 7E-05
USP50-TRPM7 rs8042919 15 50,878,630 A/G 0.097 95,626 -0.57 (0.14) 4E-05
CREBBP rs143903106 16 3,336,067 T/G 0.001 95,626 4.10 (1.46) 5E-03
LITAF rs8049607 16 11,691,753 T/C 0.503 95,626 1.05 (0.08) 8E-44
MKL2 rs30208 16 14,428,853 T/C 0.501 95,626 0.45 (0.08) 2E-09
CNOT1 rs7188697 16 58,622,178 G/A 0.247 91,615 -1.57 (0.10) 4E-63
LIG3 rs2074518 17 33,324,382 A/G 0.428 92,753 -0.79 (0.08) 2E-21
PRKCA rs9912468 17 64,318,357 G/C 0.417 89,579 -0.68 (0.08) 2E-15
KCNJ2 rs17779747 17 68,494,992 T/G 0.304 93,948 -1.08 (0.09) 3E-37
KCNE1 rs727957 21 35,880,072 T/G 0.168 95,626 0.48 (0.11) 3E-05
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Nonsynonymous QTIGC Validated RNF207(c) RNF207 RNF207 GPR153
Intronic QTIGC Validated TCEA3(t) TCEA3, ASAP3
Intergenic QTIGC Validated
Intronic QTIGC Validated ATP1B1(ti), NME7(t) NME7
Intergenic QTIGC-only SLC8A1(p) THUMPD2
Nonsynonymous QTIGC-only SP3
Nonsynonymous QTIGC Validated CCDC141(i), TTN(i) TTN FKBP7, PRKRA
Nonsynonymous QTIGC-only SPATS2L(t), SGOL2(p)









Intergenic QTIGC-only FAM13B(t), ETF1(p) MYOT, FAM13B
Nonsynonymous QTIGC-only GMPR(c), ATXN1(tp), GMPR GMPR
Intergenic QTIGC Validated PLN(i) PLN SSXP10
Intronic QTIGC Validated CAV1(pi), CAV2(pi) AC002066.1















VPS29(t), GPN3(t), ARPC3(t), 
C12ORF24(t), ATP2A2(pi)
GIT2, TCTN1 ATP2A2, PPTC7
Intronic QTIGC Validated KLF12(t) KLF12





Intergenic QTIGC Validated LITAF(t) LITAF
Intergenic QTIGC Validated
Intronic QTIGC Validated NDRG4(t), CNOT1(t), GOT2(i) SETD6, NDRG4
Intronic QTIGC Validated LIG3(t), CCT6B(t), UNC45B(i)
LIG3, CCT6B, RFFL, 
RP5-837J1.2




Nearby Gene SNV Chr Pos
Coded/ 
Noncoded Allele CAF N
Effect in ms 
(SE) Pvalue
PM20D1 rs1361754 1 205,801,872 G/A 0.511 95,626 0.47 (0.08) 1E-09
SLC4A3 rs55910611 2 220,500,412 A/G 0.006 74,508 -3.06 (0.61) 2E-07
CASR rs1801725 3 122,003,757 T/G 0.126 95,626 -0.58 (0.12) 4E-08
ZNF37A rs4934956 10 38,814,815 T/C 0.497 70,792 0.58 (0.10) 2E-10
NRAP rs3189030 10 115,393,929 A/G 0.299 95,626 -0.48 (0.09) 4E-08
GOSR2 rs17608766 17 45,013,271 C/T 0.123 95,626 0.72 (0.12) 3E-09
SENP2 rs6762208 3 185,331,165 A/C 0.358 92,046 0.44 (0.08) 2E-07
SLC12A7 rs737154 5 1,065,399 C/T 0.500 92,046 -0.40 (0.08) 2E-07
CDKN1A rs9470361 6 36,623,379 A/G 0.249 92,046 -0.76 (0.09) 2E-15
NACA rs2926743 12 57,114,100 A/G 0.252 92,046 0.53 (0.09) 6E-08






Nonsynonymous QT Novel N/A PM20D1
PM20D1, NUCKS1, 
RAB7L1, SLC41A1
Nonsynonymous QT Novel N/A SLC4A3
Nonsynonymous QT Novel N/A CASR CSTA
Intergenic QT Novel N/A
Nonsynonymous QT Novel N/A NRAP NRAP CASP7
UTR3 QT Novel N/A RPRML
Nonsynonymous JT Novel N/A SENP2
Splicing/ 
Synonymous
JT Novel N/A SLC12A7 NKD2
Intergenic JT Novel N/A
Nonsynonymous JT Novel N/A NACA RBMS2
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Table 3.2: Exploration of the SCN5A-SCN10A Locus
Table 3.2a lists the 3 exome-wide significant coding variants in the 
SCN5A-SCN10A locus from the all ancestries QT association. Table 3.2b 
contains the result of running GWiS on all 413 variants in the locus from 
the European ancestry-only QT association. 4 variants representing 4 
independent effects in the locus are shown with one of them being 
represented by a coding variant in SCN10A. “R2” is the r-squared 
between the SNV being added to the model and the previous SNV held in 
the model (or zero for the first SNV). “# Tests” is the effective number of 
independent tests in the locus, which is fewer than “SNPs Tested” due to 
LD between SNVs.
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DLEC1 rs116202356 3 38,103,776 G/A 0.02 95,626 2.22 3E-11 Nonsynonymous
SCN5A rs1805124 3 38,645,420 T/C 0.24 95,626 0.66 7E-12 Nonsynonymous
SCN10A rs6795970 3 38,766,675 A/G 0.37 95,626 -0.67 3E-17 Nonsynonymous
Nearby 
Gene SNV Chr Pos
SNPs 
Tested # Tests N R2 Pvalue Function
SCN5A rs12053903 3 38,593,393 413 365.28 83,884 0.000 9E-28 Intronic
SCN5A rs3922844 3 38,624,253 413 365.28 81,011 0.002 3E-18 Intronic
SCN10A rs6795970 3 38,766,675 413 365.28 83,884 0.001 2E-16 Nonsynonymous
rs9851724 3 38,719,935 413 365.28 70,434 0.010 9E-12 Intergenic
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Table 3.3: Cohort Demographics
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The Atherosclerosis Risk 
in Communities Study
The Atherosclerosis Risk in 
Communities Study
British Genetics of 
Hypertension
N, participants after exclusion 2381 10246 3567 821
Sex, women, % 61.74 53.85 62.88 60.9
Age, years, mean±SD 76.12±5.405 54.2±5.683 53.37±5.788 57.54±10.65
Age, min-max 66-95 44-66 44-66 22-85
Height, cm, mean±SD 166.4±9.152 168.5±9.394 167.9±8.876 165.9±9.05
BMI, kg/m2, mean±SD 27.09±4.464 26.99±4.862 29.59±6.17 27.42±3.84
Heart rate, bpm, mean±SD 66.45±11.38 66.15±9.815 66.58±11.01 63.97±11.5
QT interval, ms, mean±SD 405.3±34.47 398.8±28.97 400±33.01 421.9±24.4
QT interval, ms, min-max 292-584 288-646 308-696 363-531
JT interval, ms, mean±SD 314±33.49 307.6±28.67 310±32.48 328.4±23.97
JT interval, ms, min-max 214-492 208-556 212-612 266-448
Study design Population-based Population-based Hypertensive cases
Ethnicity and origin
Americans with European 
Ancestry
Americans with African 
Ancestry
White Europeans from 
UK
Exome Chip version “1.0” “1.0” “1.0” “1.0”
Genotype calling software centrally at CHARGE centrally at CHARGE centrally at CHARGE GenCall and zCall




Related individuals (yes/no)? No No No No
Familial adjustment method (if applicable) N/A N/A N/A N/A
Population stratification assessment and 
adjustment
2 PCs 10 PCs 10 PCs 10 PCs
Analysis software version (e.g. seqMeta 
v1.6.0)
seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0 R (3.01), seqMeta (1.3)
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CAMP CHS – EA CHS – AA ERF FHS
MGH Cardiology and Metabolic 
Patient Cohort
The Cardiovascular Health Study
The Cardiovascular Health 
Study
Erasmus Rucphen Family 
Study
Framingham Heart Study
2873 3363 648 965 7062
41.7 59.41 64.51 55.23 54.87
61.6±11.4 72.42 ( 5.43 ) 72.57 ( 5.64 ) 48.14 (14.30) 39.33±9.87
31-81 65-100 65-93 16.65 - 85.27 19-72
171.5±10.1 164.6 ( 9.36 ) 164.27 ( 9.08 ) 167.60 (9.48) 168.93±9.54
28.75±5.85 26.32 ( 4.48 ) 28.48 ( 5.5 ) 26.82 (4.59) 26.10±4.98
66.82±12.10 64.36 ( 10.23 ) 67.51 ( 11.49 ) 62.89 (10.41) 68.97±13.64
417.15±23.00 414.99 ( 32.22 ) 407.28 ( 34.96 ) 398.82 (28.20) 393.19±36.77
336-574 308-544 312-540 304 - 520 260-610
327.97±24.71 326.16 ( 31.47 ) 319.56 ( 34.87 ) 301.37 (27.34) 328±30
253-482 212-452 216-456 200 - 408 217-511
Population-based Population-based Population-based Population-based family Population-based 
European Ancestry
Americans with European 
Ancestry
Americans with African Ancestry European




“1.0” “1.0” “1.1” “1.0”
GeneCall + Zcall centrally at CHARGE centrally at CHARGE zCall centrally at CHARGE




No No No Yes Yes
N/A N/A N/A
adjusted for kinship matrix in 
seqMeta
famSKAT
10 PCs 10 PCs 10 PCs NA 10 PCs
seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0
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GS:SFHS GOCHA GRAPHIC Inter99
Generation Scotland: Scottish 
Family Health Study
Genetics of Cerebral Hemorrhage with Anticoagulation
The Genetic Regulation of 
Arterial Pressure of Humans 
in the Community
Inter99
9027 360 1736 5695
59.3 195 (54.2) 49.06 52.1
51.83, 13.57 73.2±8.3 39.07±14.52 46.2±7.9
18-80 48-100 18-61 29.7-61.3
167.6, 9.54 168.5±10.5 171.08±9.47 172.2±9.1
26.95, 5.17 26.1±4.6 26.03±4.62 26.3±4.7
69.65, 11.36 68.3±13.7 66.0±10.34 67.0±10.9
405.92, 30.99 428.6±30.6 404.05±19.91 403.5±26.8
304-552 373-667 343-469 310-538
316.49, 30.56 N/A 301.80±27.88 312.5±26.7
216-464 N/A 228-406 228-436
Population-based with families Population-based Population-based Population-based 





Beadstudio-Gencall v3.0 Zcall at Broad gencall/zcall GenCall and zCall
ID call rate >97%, SNP call rate filter 
98%, HWE cutoff <1E-6
Samples excluded missing>2%, mismatch gender, and first- 
or second-degree relatives identified based on identity-by-
descent allele sharing (pi-hat>0.185). Variants call rate<95%, 
mean heterozygosity >±3sd, departure from Hardy-Weinberg 
equilibrium at p<1×10-6 in control subjects, or differential 
missingness in cases and controls were excluded. All SNPs 
were aligned on the forward strand and coded to the same 
minor alleles in both datasets.
As in the FINAL.CHARGE-
EX.EKG.QTAnalysisPlan
Exclusion criteria: SNPs 1) Call 
rate >98%; 2) HWE P >10-4; 
Individuals: 1) Heterozygosity was 
calculated separately for maf < 1% 
and maf > 1% and samples were 
dropped judged by plots; 2) 
Cryptic relatedness (related to 20 
or more individuals).
Yes No Yes No
Kinship matrix N/A Kinship N/A
N/A 2 PCs 10 PCs
seqMeta v1.6.5 seqMeta v1.5.0 seqMeta seqMeta v1.5
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JHS KORA CROATIA-Korcula Lifelines MESA – EA
The Jackson Heart Study
Kooperative Gesundheitsforschung in der Region 
Augsburg




2216 2672 295 1943 2324
62.54 52.3 62.4 59.59 53.7
53.06±12.69 48.8±13.1 54.23, 13.38 45.27±13.09 62.36±10.17
21-91 25-74 18-88 18-87 44-84
169.35±9.34 168.3±9.3 168.3, 8.91 174.66±9.32 168.4±9.266
31.34±6.42 27.0±4.4 27.99, 4.24 25.89±4.55 27.66±5.354
68.39±10.14 65.1±10.2 65.85, 9.44 68.65±11.06 66.26±10.14
414.14±31.62 407.5±26.7 401.64, 29.44 393.53±26.89 399.1±30.07
290-580 316-542 270.0-510.0 289-525 334-538
320.37±30.46 315.7±26.6 305.79, 29.36 299.92±26.79 319.32±28.65
212-466 234-442 176.0-408.0 202-415 240-438
Mixed family and population-based Population-based Isolate population Population-based Population-based 
African American European / Germany
European-ancestry from 
Croatian island of 
Korcula
European, Netherlands
“1.0” “1.0” HumanExome-12v1_A “1.1” “1.0”




sample selection based on genCall+zCall following 
SOP v5
ID call rate >97%, SNP 
call rate filter 98%, HWE 
cutoff <1E-6
GeneCall + Zcall; SNP 
Callrate≥95%, HWE>10-6, 
Sample Callrate<95%, on 
PCA outliers, duplicates, 




Yes No Yes No No
Kinship adjustment N/A Kinship matrix N/A N/A
10 PCs
pairwise exclusion of samples with 
PI_HAT>0.1875, keep sample with higher callrate
N/A 5 PCs 2 PCs
seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.5 seqMeta v1.6.0 seqMeta v1.6.0
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MESA – AA MESA – HA MESA – CH NEO RS







The Netherlands Epidemiology 
of Obesity (NEO) Study
The Rotterdam Elderly Study
1501 1382 750 6047 2419
54.9 52.6 51.6 52.03 55.25
62.06±10.03 61.16±10.24 62.21±10.37 56.0±5.94 68.6±8.363
45-84 44-84 44-84 44-66 55-101
168.36±9.52 161.68±9.34 161.49±8.58 173.62±9.59 167.5±9.384
30.1±5.88 29.5±5.15 23.99±3.29 30.05±4.82 26.21±3.591
63.01±10.28 63.5±9.39 63.06±8.63 65.7±11.39 70.73±12.28
410.33±31.73 408.8±29.75 410.97±29.38 406.6±30.5 396.7±29.197
320-512 328-530 334-554 244-666 282-524
319.4±30.99 317.79±29.42 321.67±29.55 312.9±28.7 299.82±28.158
240-420 238-428 256-450 188-484 196-416
Population-based Population-based Population-based Population-based Population-based 
European Ancenstry from the 
Netherlands
Europeans with European Ancestry
“1.0” “1.0” “1.0” HumanCoreExome-24v1-0 “1.0”
centrally at CHARGE centrally at CHARGE
centrally at 
CHARGE
GenCall centrally at CHARGE
centrally at CHARGE centrally at CHARGE
centrally at 
CHARGE
Outlying individuals were 
excluded on the basis of 
relatedness, non-European 
ancestry, sex discrepancy and 
heterzygosity
centrally at CHARGE
No No No No No
N/A N/A N/A N/A N/A
2 PCs 2 PCs 2 PCs 10 PCs 5 PCs
seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.5 seqMeta v1.6.0
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SHIP TwinsUK UHP












Population-based Twin study Population-based 
EA from Germany
European ancestry, individuals from 
the United Kingdom
Dutch citizens of European Ancestry
“1.0” “1.0” 1.1
Gencall (Illumina Genome Studio), followed by zCall Gencall GenomeStudio and zCall
Samples: Genotype call rate <98%; High heterozygosity and/or 
implausible high crypted relatedness; IBS clustering, Unexpected 
duplicates; Sex mismatches
Variants: Call rate <95%; HWE p-value < 10E-4
Excluded sampels with callrate < 97%, 
removed autosomal heterozygosity 
outliers (+/- 4SD (calculated for 
variants with MAF <1% and MAF >=1% 
separately) , gender mismatches, 
duplicates as established by identity by 
descent (IBD) analysis, ethnic outliers 
as determined by combining with 1000 
Genomes Project data (PCA), GWAS 
concordance (when available). Removed 
variants with call rate < 95% and 
pHWE< 1x10-6.
Plink v1.07 was used for QC. Samples with 
missing SNP rate >5% or discordant sex were 
excluded. Using SNPs with missingness<1%, 
MAF>5%, Hardy-Weinberg P<0.001, LD-pruned 
r2>0.2, we removed samples with heterozygosity 
> 4 standard deviations from the mean, related 
samples randomly, and samples from non-
European descent based on manual inspection 
of PCA results that were calculated with 
Eigensoft. SNPs with missing rates>5% or 




10 PCs 10 PCs 1 PC
seqMeta v1.4.0 (seqMeta v1.3.0 for QT analysis) seqMeta v1.3 seqMeta v1.6.0
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WHI – EA WHI – AA YFS












Population-based Population-based Population-based 
Americans with European 
Ancestry
Americans with African 
Ancestry
Finnish with European Ancestry
“1.0” “1.0” CoreExome v1.0
GenomeStudio




2 PCs 2 PCs 4 PCs
seqMeta v1.6.0 seqMeta v1.6.0 seqMeta v1.3.0
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Table 3.4: Conditional Analyses in European Ancestry-only ARIC
Conditional analyses with this studies representative SNV and QTIGC’s 
representative SNV in the same QT interval model. EC=ExomeChip (this 
study). Con=conditional analysis. The “Con Survive” column indicates if 
the ExomeChip SNV or QTIGC SNV or both have effect size estimates the 
remain about the same in the conditional model. LD calculations are 
performed in the merged ExomeChip and HapMap-imputed most likely 
genotype ARIC Europeans dataset with 9,537 samples. Conditional 
analyses were run in the same ARIC Europeans dataset, however limited 
to 9,005 individuals due to phenotype exclusions. Effect sizes are in 
milliseconds. EC Pos column is position from GRCh37.
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Nearby 
Gene Chr EC Pos EC SNV EC Function QTIGC SNV
LD b/w 










RNF207 1 6,278,414 rs709209 Nonsynonymous rs846111 0.696 1.11 1.38 0.16 1.23 QTIGC
SP3 2 174,820,750 rs1047640 Nonsynonymous rs938291 0.218 1.11 0.77 0.75 0.52 Both
TTN-
CCDC141
2 179,575,511 rs72648998 Nonsynonymous rs7561149 0.044 1.29 -0.12 1.30 0.01 EC
SPATS2L 2 201,303,848 rs192861441 Nonsynonymous rs295140 0.002 -2.98 0.59 -2.78 0.57 Both
C3ORF75 3 47,282,303 rs2276853 Nonsynonymous rs17784882 0.900 -0.34 -0.41 0.53 -0.91 QTIGC
SMARCAD1 4 95,173,779 rs7439869 Nonsynonymous rs3857067 0.539 0.63 -0.65 0.33 -0.41 QTIGC
GMPR 6 16,290,761 rs1042391 Nonsynonymous rs7765828 0.989 -0.50 0.52
KCNH2 7 150,645,534 rs1805123 Nonsynonymous rs2072413 0.823 -1.32 -1.43 0.17 -1.58 QTIGC
LAPTM4B 8 99,045,866 rs17831160 Nonsynonymous rs11779860 0.004 -0.24 -0.33 -0.18 -0.33 Both
AZIN1 8 104,432,659 rs143025416 Nonsynonymous rs1961102 0.000 15.26 0.53 15.08 0.53 Both
GBF1 10 104,174,986 rs143226354 Splicing/ Nonsynonymous rs2485376 0.000 -0.28
ATP2A2 12 110,383,141 rs11068997 Nonsynonymous rs3026445 0.018 -0.07 0.46 0.11 0.46 QTIGC
USP50-
TRPM7
15 50,878,630 rs8042919 Nonsynonymous rs3105593 0.099 -0.41 0.67 -0.08 0.66 QTIGC
CREBBP 16 3,336,067 rs143903106 Nonsynonymous rs1296720 0.000 0.63 0.98 0.32 0.97 QTIGC
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Table 3.5: All Exome-wide Significant Coding Variants
Table layout similar to Table 3.1. All coding variants that pass a 
Bonferroni correction of p-value < 2E-07. Part A contains results from 
the QT interval association and part B contains results from the JT 
interval association. Pos column is position from GRCh37. Gene column 
is the gene the variant is in (not a nearby gene or locus label like other 
tables in this study).
74






RNF207 rs709209 1 6,278,414 A/G 0.38 95,626 1.23 1E-48 Nonsynonymous
RNF207 rs846111 1 6,279,370 G/C 0.24 76,129 1.51 2E-46 Nonsynonymous
F5 rs6027 1 169,483,561 T/C 0.05 74,803 -1.27 1E-10 Nonsynonymous
F5 rs6018 1 169,511,878 T/G 0.05 73,622 -1.25 1E-09 Nonsynonymous
F5 rs6033 1 169,521,853 A/G 0.07 95,626 -0.87 1E-08 Nonsynonymous
PM20D1 rs1361754 1 205,801,872 A/G 0.49 95,626 0.47 1E-09 Nonsynonymous
TTN rs72648998 2 179,575,511 C/T 0.05 95,626 1.00 3E-09 Nonsynonymous
TTN rs10497520 2 179,644,855 T/C 0.18 92,753 0.63 9E-09 Nonsynonymous
SLC4A3 rs55910611 2 220,500,412 G/A 0.01 74,508 -3.06 2E-07 Nonsynonymous
DLEC1 rs116202356 3 38,103,776 G/A 0.02 95,626 2.22 3E-11 Nonsynonymous
SCN5A rs1805124 3 38,645,420 T/C 0.24 95,626 0.66 7E-12 Nonsynonymous
SCN10A rs6795970 3 38,766,675 A/G 0.37 95,626 -0.67 3E-17 Nonsynonymous
CASR rs1801725 3 122,003,757 G/T 0.13 95,626 -0.58 4E-08 Nonsynonymous
CEP85L rs3734382 6 118,886,961 G/T 0.26 95,626 -0.63 4E-13 Nonsynonymous
CEP85L rs3734381 6 118,887,303 T/C 0.46 91,615 -1.00 4E-36 Nonsynonymous
KCNH2 rs1805123 7 150,645,534 T/G 0.21 95,626 -1.47 7E-51 Nonsynonymous
NRAP rs3189030 10 115,393,929 G/A 0.30 95,626 -0.48 4E-08 Nonsynonymous
NRAP rs2185913 10 115,410,234 T/C 0.27 95,626 -0.48 2E-07 Nonsynonymous
KCNQ1 rs17215500 11 2,790,111 C/T 0.00 95,626 46.38 1E-11 Stop
CCT6B rs2230553 17 33,269,648 C/G 0.34 89,579 -0.56 2E-10 Nonsynonymous
CCT6B rs9635769 17 33,288,363 C/T 0.45 95,626 0.47 3E-08 Nonsynonymous






RNF207 rs709209 1 6,278,414 A/G 0.38 92,046 0.22 2E-52 Nonsynonymous
RNF207 rs200882245 1 6,279,316 C/T 0.00 92,046 -2.76 2E-08 Nonsynonymous
RNF207 rs846111 1 6,279,370 G/C 0.24 72,859 0.52 6E-50 Nonsynonymous
F5 rs6027 1 169,483,561 T/C 0.05 71,223 -0.57 4E-11 Nonsynonymous
F5 rs6018 1 169,511,878 T/G 0.05 70,404 -0.56 1E-10 Nonsynonymous
F5 rs6037 1 169,513,583 G/T 0.07 72,538 -0.45 8E-08 Synonymous
F5 rs6033 1 169,521,853 A/G 0.07 92,046 -0.51 2E-09 Nonsynonymous
TTN rs72648998 2 179,575,511 C/T 0.05 92,046 0.36 2E-09 Nonsynonymous
TTN rs34819099 2 179,628,918 C/T 0.01 92,046 0.87 6E-08 Nonsynonymous
TTN rs10497520 2 179,644,855 T/C 0.18 89,173 0.10 1E-08 Nonsynonymous
SLC4A3 rs55910611 2 220,500,412 G/A 0.01 70,928 -3.24 6E-08 Nonsynonymous
DLEC1 rs116202356 3 38,103,776 G/A 0.02 92,046 1.33 2E-18 Nonsynonymous
SLC22A14 rs2070492 3 38,357,817 C/T 0.10 92,046 -0.14 4E-08 Nonsynonymous
SCN5A rs1805124 3 38,645,420 T/C 0.24 92,046 0.12 5E-25 Nonsynonymous
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SCN10A rs12632942 3 38,764,998 A/G 0.25 92,046 0.08 1E-07 Nonsynonymous
SCN10A rs6795970 3 38,766,675 A/G 0.36 92,046 -0.33 1E-34 Nonsynonymous
SCN10A rs57326399 3 38,768,300 T/C 0.24 92,046 0.12 2E-10 Nonsynonymous
CASR rs1801725 3 122,003,757 G/T 0.12 92,046 -0.22 2E-09 Nonsynonymous
SENP2 rs6762208 3 185,331,165 C/A 0.36 92,046 0.04 2E-07 Nonsynonymous
SLC12A7 rs737154 5 1,065,399 C/T 0.50 92,046 -0.10 2E-07
Splicing/Synonymo
us
CEP85L rs3734382 6 118,886,961 G/T 0.26 92,046 -0.13 2E-08 Nonsynonymous
CEP85L rs3734381 6 118,887,303 T/C 0.46 88,035 -0.14 3E-25 Nonsynonymous
KCNH2 rs1805123 7 150,645,534 T/G 0.21 92,046 -0.62 1E-51 Nonsynonymous
NRAP rs3189030 10 115,393,929 G/A 0.30 92,046 -0.09 3E-08 Nonsynonymous
NRAP rs2185913 10 115,410,234 T/C 0.27 92,046 -0.07 6E-08 Nonsynonymous
KCNQ1 rs17215500 11 2,790,111 C/T 0.00 92,046 3.99 6E-12 Stop
NACA rs2958149 12 57,109,792 A/G 0.25 88,035 0.13 8E-08 Nonsynonymous
NACA rs2926743 12 57,114,100 A/G 0.25 92,046 0.14 6E-08 Nonsynonymous
CCT6B rs2230553 17 33,269,648 C/G 0.34 86,309 -0.13 5E-09 Nonsynonymous
CCT6B rs9635769 17 33,288,363 C/T 0.45 92,046 0.09 2E-08 Nonsynonymous
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Table 3.6: GWiS Results
Table contains the result of running GWiS on all variants in each locus 
from the European ancestry-only QT interval association (or JT interval 
association for the last four). The SNVs are added into the GWiS model in 
the order they are listed. “R2” is the r-squared between the SNV being 
added to the model and the previous SNV held in the model (or zero for 
the first SNV). “# Tests” is the number of independent tests are by the 
model, which is less than “SNPs Tested” do to LD between SNVs. For the 
35 previously identified loci, LD calculations are shown in Table 3.5 
between the QTIGC representative SNV and each of the independent 
representative SNVs picked by GWiS. LD calculations are performed in 
the merged ExomeChip and HapMap-imputed ARIC Europeans dataset 
with 9,537 samples. LD is made bold if >0.5. Row color banding in for 
each locus. Gene column is the gene the variant is in (not a nearby gene 
or locus label like other tables in this study). The order of the loci is the 
same as Table 3.1. Pos column is position from GRCh37.
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Gene SNV Chr Pos
SNPs 





RNF207 rs709209 1 6,278,414 191 175.55 83,884 0.000 1E-50 Nonsynonymous 0.696
RNF207 rs200882245 1 6,279,316 191 175.55 83,884 0.001 1E-07 Nonsynonymous 0.001
ASAP3 rs1077514 1 23,766,233 241 208.24 81,011 0.000 3E-09 Intronic 0.060
rs12143842 1 162,033,890 214 195.06 83,884 0.000 2E-258 Intergenic 0.989
NOS1AP rs4657178 1 162,210,610 214 195.06 83,884 0.055 2E-104 Intronic 0.053
NOS1AP rs16857031 1 162,112,910 214 195.06 77,837 0.067 2E-70 Intronic 0.047
ATP1B1 rs10919071 1 169,099,483 182 160.22 83,884 0.000 5E-32 Intronic 0.964
SLC8A1 2 39,959,060 26 25.38
SP3 rs1047640 2 174,820,750 79 77.97 83,884 0.000 2E-06 Nonsynonymous 0.218
TTN rs72648998 2 179,575,511 651 482.16 83,884 0.000 3E-09 Nonsynonymous 0.044
TTN rs72646869 2 179,446,381 651 482.16 83,884 0.002 7E-07 Nonsynonymous 0.017
TTN rs16866378 2 179,393,111 651 482.16 83,884 0.001 8E-07 Nonsynonymous 0.009
SPATS2L 2 201,303,848 140 129.2
SCN5A rs12053903 3 38,593,393 413 365.28 83,884 0.000 9E-28 Intronic 0.970
SCN5A rs3922844 3 38,624,253 413 365.28 81,011 0.002 3E-18 Intronic 0.002
SCN10A rs6795970 3 38,766,675 413 365.28 83,884 0.001 2E-16 Nonsynonymous 0.001
rs9851724 3 38,719,935 413 365.28 70,434 0.010 9E-12 Intergenic 0.000
C3ORF75 3 47,282,303 327 279.96
SLC4A4 rs7689609 4 72,083,374 160 148.66 75,316 0.000 6E-08 Intronic 0.673
SMARCAD1 rs7439869 4 95,173,779 52 45.25 83,884 0.000 1E-06 Nonsynonymous 0.539
GFRA3 5 137,441,767 136 124.32
GMPR rs1042391 6 16,290,761 61 57.99 77,837 0.000 1E-06 Nonsynonymous 0.989
rs11153730 6 118,667,522 104 95.86 83,884 0.000 1E-76 Intergenic 0.988
rs12210810 6 118,653,204 104 95.86 77,837 0.055 2E-36 Intergenic 0.050
CAV1 rs3807989 7 116,186,241 93 87.79 83,884 0.000 4E-10 Intronic 0.168
KCNH2 rs1805123 7 150,645,534 316 285.07 83,884 0.000 7E-52 Nonsynonymous 0.823
rs4725982 7 150,637,863 316 285.07 83,884 0.087 2E-48 Intergenic 0.088
NCOA2 8 71,164,680 91 87.98
LAPTM4B 8 99,045,866 117 112.95
AZIN1 8 104,432,659 81 76
GBF1 10 104,174,986 187 167.45
KCNQ1 rs2074238 11 2,484,803 210 197.04 77,542 0.000 3E-127 Intronic 0.021
KCNQ1 rs12296050 11 2,489,342 210 197.04 83,884 0.018 8E-64 Intronic 0.992
KCNQ1 rs17215500 11 2,790,111 210 197.04 83,884 0.000 5E-09 Stop 0.000
KCNQ1 rs800336 11 2,473,131 210 197.04 81,011 0.018 4E-18 Intronic 0.000
FADS2 rs1535 11 61,597,972 439 394.13 83,884 0.000 5E-10 Intronic 0.952
GIT2 rs11068997 12 110,383,141 182 166.36 83,884 0.000 6E-07 Nonsynonymous 0.018
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TCTN1 rs75714509 12 111,080,097 182 166.36 83,884 0.000 2E-06 Nonsynonymous 0.018
KLF12 rs1886512 13 74,520,186 25 23.82 68,810 0.000 8E-11 Intronic 0.955
ANKRD9 14 102,808,655 154 136.31
USP50-
TRPM7 15 50,878,630 177 165.09
CREBBP 16 3,336,067 507 450.41
rs8049607 16 11,691,753 173 159.82 83,884 0.000 1E-41 Intergenic 0.736
rs30208 16 14,428,853 63 60.45 83,884 0.000 2E-11 Intergenic 0.342
CNOT1 rs7188697 16 58,622,178 196 184.33 80,521 0.000 8E-65 Intronic 0.984
LIG3 rs2074518 17 33,324,382 281 255 81,011 0.000 4E-20 Intronic 0.994
PRKCA rs9912468 17 64,318,357 95 88.61 77,837 0.000 3E-12 Intronic 0.993
rs17779747 17 68,494,992 27 26.89 83,884 0.000 2E-37 Intergenic 0.388
KCNE1 21 35,880,072 129 118.75
Gene SNV Chr Pos
SNPs 





PM20D1 rs1361754 1 205,801,872 228 206.79 83,884 0.000 4E-10 Nonsynonymous N/A
SLC4A3 rs55910611 2 220,500,412 500 436.51 64,444 0.000 2E-07 Nonsynonymous N/A
STK11IP rs620698 2 220,466,199 500 436.51 81,011 0.000 9E-07 Intronic N/A
CASR rs1801725 3 122,003,757 322 275.41 83,884 0.000 5E-08 Nonsynonymous N/A
rs4934956 10 38,814,815 30 26.77 61,376 0.000 3E-11 Intergenic N/A
NRAP rs3189030 10 115,393,929 232 204.8 83,884 0.000 7E-08 Nonsynonymous N/A
GOSR2 rs17608766 17 45,013,271 117 108.08 83,884 0.000 5E-09 UTR3 N/A
SENP2 rs6762208 3 185,331,165 156 142.15 80,330 0.000 2E-10 Nonsynonymous N/A
SLC12A7 rs737154 5 1,065,399 272 245.21 80,330 0.000 1E-06
Splicing/Synonym
ous N/A
rs9470361 6 36,623,379 223 207.83 80,330 0.000 5E-15 Intergenic N/A
NACA rs2926743 12 57,114,100 554 482.89 80,330 0.000 2E-08 Nonsynonymous N/A
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3.7 Methods
Genotyping and Quality Control
Followed ExomeChip best practices put out by the CHARGE Consortium 
(Grove et al.).
Association Analyses and Meta-Analysis
All cohorts excluded individuals with QRS intervals greater than or 
equal to 120ms, heart rate less than 40 beats per minute (bpm) or 
greater than 120bpm, left or right bundle branch block, atrial fibrillation 
on baseline EKG, Wolff–Parkinson–White syndrome (WPW), pacemaker, 
take class I and class III blocking medication, or are pregnant. Clinical 
characteristics summary statistics for each cohort are provided in Table 
3.3.
Effect size estimates are determined via standard inverse variance 
weighted meta-analysis on a linear association model with ventricular 
repolarization time as the outcome using covariates: Age, Sex, RR 
interval, Height, BMI, and cohort specific adjustments (principal 
components, clinic, family structure). Significance (p-value) is 
determined by first inverse rank normal transforming residuals from a 
linear model with ventricular repolarization time as the outcome using 
covariates: Age, Sex, RR interval, Height, and BMI, then running a 
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standard inverse variance weighted meta-analysis on a linear association 
model with the transformed residuals as the outcome using cohort 
specific adjustments as covariates. These two models are used in tandem 
to avoid p-value inflation from the analysis of the rare variants on the 
ExomeChip while maintaining the easy interpretation of effect sizes in 
milliseconds.
Representative single nucleotide variants (SNVs) have the lowest p-
value in each locus. QT loci are considered discovered if passing a 
Bonferroni correction, p-value < 0.05 / 209,835 SNVs (2E-07). JT loci are 
considered discovered if passing a Bonferroni correction, p-value < 0.05 / 
208,700 SNVs (2E-07). The difference in the number of SNVs is due to 
the fact not all cohorts that contributed data to the QT analysis 
contributed data to the JT analysis. Cohorts contribute slightly different 
number of SNVs do to individual QC efforts.
LD Calculations and Conditional Analyses
LD calculations are performed in the merged ExomeChip and 
HapMap-imputed ARIC Europeans dataset with 9,537 samples.
Utilization of Variants to Implicate Genes using GWiS
Gene-Wide Significance (GWiS) (Huang et al.) tests are performed 
by defining each locus as a “gene” and running on European-only 
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summery statistics from 22 cohorts for a sample size of 83,884 in QT 
analyses and 80,330 in JT analyses. GWiS finds the number of 
independent effects in each locus along with a SNV that best represents 
each independent effect. This is important because even coding variants 
are effected by LD causing them to appear significant in the analysis due 
to the true variant driving the association being nearby. The LD 
information needed by GWiS was estimated in the ARIC Europeans 
dataset. An attempt to replace non-coding variants with coding variants 
in r2>0.8 LD, however this yielded no substitutions.
GTEx eQTL Lookup
We looked up each of the Table 3.1 representative SNVs and GWiS 
independent SNVs (60 SNVs) in the GTEx Portal for single-tissue 
expression quantitative trait loci (eQTL). All genes passed FDR<5%. The 
result is a list of nearby genes that the loci the SNV is in is known to 
effect the mRNA expression of (Table 3.1). If the expression effect was 
observed in left ventricle, we made the gene name bold in the table. 
Genes were excluded if the SNV was towards the bottom of an LD 
significance peak: ATP1B1, ANKRD9, BAZ2A from the NACA locus.
3.8 Cohort Specific Methods
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AGES
In anticipation of the sequencing of the human genome and description 
of the human proteome, the Age, Gene/Environment Susceptibility-
Reykjavik Study (AGES-Reykjavik) (Tamara B Harris et al., “Age, 
Gene/Environment Susceptibility-Reykjavik Study”) was initiated in 
2002. AGES-Reykjavik was designed to examine risk factors, including 
genetic susceptibility and gene/environment interaction, in relation to 
disease and disability in old age. The study is multidisciplinary, 
providing detailed phenotypes related to the cardiovascular, 
neurocognitive (including sensory), and musculoskeletal systems, and to 
body composition and metabolic regulation. Relevant quantitative traits, 
subclinical indicators of disease, and medical diagnoses are identified by 
using biomarkers, imaging, and other physiologic indicators. The AGES-
Reykjavik sample is drawn from an established population-based cohort, 
the Reykjavik Study. This cohort of men and women born between 1907 
and 1935 has been followed in Iceland since 1967 by the Icelandic Heart 
Association. The AGES-Reykjavik cohort, with cardiovascular risk factor 
assessments earlier in life and detailed late-life phenotypes of 
quantitative traits, will create a comprehensive study of aging nested in a 
relatively genetically homogeneous older population. This approach 
should facilitate identification of genetic factors that contribute to 
healthy aging as well as the chronic conditions common in old age.
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ARIC
The Atherosclerosis Risk in Communities study 
(http://www.cscc.unc.edu/aric/) includes 15,792 men and women from 
four communities in the United States (Jackson, Mississippi; Forsyth 
County, North Carolina; Washington County, Maryland; suburbs of 
Minneapolis, Minnesota) enrolled in 1987–1989 and prospectively 
followed. EKGs were recorded at baseline using MAC PC EKG machines 
(Marquette Electronics) and processed initially by the Dalhousie EKG 
program in a central laboratory at the EPICORE Center (University of 
Alberta). Processing was later repeated for the present study using the 
GE Marquette 12-SL program (2001 version) at the EPICARE Center 
(Wake Forest University). All EKGs were visually inspected for technical 
errors and inadequate quality (“The Atherosclerosis Risk in Communities 
(ARIC) Study”).
BRIGHT
The BRIGHT study (Caulfield et al.) includes 2000 unrelated white 
European hypertensive individuals. Twelve-lead EKG recordings 
(Siemens-Sicard 440; http://www.brightstudy.ac.uk/info/sop04.html) 
producing automated measurements of the JT and QT interval were 
available for all subjects. All data were subsequently transferred from 
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each recruitment centre by electronic modem to electrophysiologists from 
the West of Scotland Primary Prevention Study (Professor Peter 
MacFarlane) for central reporting.
CAMP
The MGH Cardiology and Metabolic Patient Cohort is comprised of 3850 
subjects recruited from the ambulatory MGH Cardiology Practice 
between 2009 and 2012.
CHS
The Cardiovascular Health Study (CHS) is a population-based cohort 
study of risk factors for coronary heart disease and stroke in adults ≥65 
years conducted across four field centers (Fried et al.). The original 
predominantly European ancestry cohort of 5,201 persons was recruited 
in 1989-1990 from random samples of the Medicare eligibility lists; 
subsequently, an additional predominantly African-American cohort of 
687 persons were enrolled for a total sample of 5,888. CHS was approved 
by institutional review committees at each field center and individuals in 
the present analysis had available DNA and gave informed consent 




The Erasmus Rucphen Family study (Pardo et al.) is comprised of a 
family-based cohort embedded in the Genetic Research in Isolated 
Populations (GRIP) program in the southwest of the Netherlands. The 
aim of this program is to identify genetic risk factors for the development 
of complex disorders. In ERF, twenty-two families that had a large 
number of children baptized in the community church between 1850 and 
1900 were identified with the help of detailed genealogical records. All 
living descendants of these couples, and their spouses, were invited to 
take part in the study. Comprehensive interviews, questionnaires, and 
examinations were completed at a research center in the area; 
approximately 3,200 individuals participated. Examinations included 12 
lead EKG measurements. EKGs were recorded on ACTA 
electrocardiographs (ESAOTE, Florence, Italy) and digital measurements 
of the QT and JT intervals were made using the Modular EKG Analysis 
System (MEANS). Data collection started in June 2002 and was 
completed in February 2005. In the current analyses, 965 participants 
for whom complete phenotypic, genotypic and genealogical information 
was available were studied.
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FHS
The objective of the Framingham Heart Study was to identify the 
common factors or characteristics that contribute to CVD by following its 
development over a long period of time in a large group of participants 
who had not yet developed overt symptoms of CVD or suffered a heart 
attack or stroke. The researchers recruited 5,209 men and women 
between the ages of 30 and 62 from the town of Framingham, 
Massachusetts, and began the first round of extensive physical 
examinations and lifestyle interviews that they would later analyze for 
common patterns related to CVD development. Since 1948, the subjects 
have continued to return to the study every two years for a detailed 
medical history, physical examination, and laboratory tests, and in 1971, 
the Study enrolled a second generation - 5,124 of the original 
participants' adult children and their spouses - to participate in similar 
examinations. In 1994, the need to establish a new study reflecting a 
more diverse community of Framingham was recognized, and the first 
Omni cohort of the Framingham Heart Study was enrolled. In April 2002 
the Study entered a new phase, the enrollment of a third generation of 
participants, the grandchildren of the Original Cohort. In 2003, a second 
group of Omni participants was enrolled.
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Generation Scotland
The Generation Scotland: Scottish Family Health Study (GS:SFHS) 
(Smith et al.) is a collaboration between the Scottish Universities and the 
NHS, funded by the Chief Scientist Office of the Scottish Government. 
GS:SFHS is a family-based genetic epidemiology cohort with DNA, other 
biological samples (serum, urine and cryopreserved whole blood) and 
socio-demographic and clinical data from ~24,000 volunteers, aged 18-
98 years, in ~7,000 family groups. Participants were recruited across 
Scotland, with some family members from further afield, from 2006 - 
2011. Most (87%) participants were born in Scotland and 96% in the UK 
or Ireland. GS:SFHS operates under appropriate ethical approvals, and 
all participants gave written informed consent.
GOCHA
The Genetics of Cerebral Hemorrhage on Anticoagulation (GOCHA) study 
is a multicenter study comprised of patients age > 55 years presenting to 
participating hospitals with primary ICH. Controls were enrolled from 
ambulatory clinics in the same centers from which cases were recruited 




The GRAPHIC Study (Tobin et al.) comprises 2024 individuals from 520 
nuclear families recruited from the general population in Leicestershire, 
UK between 2003-2005 for the purpose of investigating the genetic 
determinants of blood pressure and related cardiovascular traits. 2 
Families were included if both parents aged 40-60 years and two 
offspring ≥18 years wished to participate. A detailed medical history was 
obtained from study subjects by standardized questionnaires and clinical 
examination was performed by research nurses following standard 
procedures. Measurements obtained included height, weight, waist-hip 
ratio, clinic and ambulatory blood pressure and a 12-lead EKG.
Inter99
The Inter99 study (Jørgensen et al.) carried out in 1999-2001 included 
invitation of 12934 persons aged 30-60 years drawn from an age- and 
sex-stratified random sample of the population. The baseline 
participation rate was 52.5%, and the study included 6784 persons. The 
Inter99 study was a population-based randomized controlled trial 
(CT00289237, ClinicalTrials.gov) and investigated the effects of lifestyle 
intervention on CVD. Here 5827 participants with information on lipids 
and exome chip were analyzed. EKG information was obtained from the 
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MUSE Cardiology Information System (GE Healthcare, Wauwatosa, 
Wisconsin) analyzed by Marquette 12SL algorithm version 21.
JHS
The Jackson Heart Study (Taylor et al.) 
(https://www.jacksonheartstudy.org/) includes 5,306 African-American 
men and women from the three counties, Hinds, Madison, and Rankin, 
that comprise the Jackson, MS metropolitan area. Participants were 
enrolled in 2000-2004 and have been followed prospectively. A supine 
12-lead digital EKG was recorded with the Marquette MAC/PC digital 
EKG recorder (Marquette Electronics, Milwaukee, Wis), and with 
electrode placement that duplicates that of the ARIC study. The EKGs 
are analyzed in accordance with the Minnesota Code Classification 
system, via an extensively validated computer algorithm that was 
developed specifically for epidemiologic studies. In-hospital surveillance 
EKGs are read visually according to the Minnesota Code Classification 
system.
KORA
KORA (Kooperative Gesundheitsforschung in der Region Augsburg) (Holle 
et al.; Wichmann et al.) is a series of independent population-based 
epidemiological surveys and follow-up studies of participants living in the 
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city of Augsburg, Southern Germany, or its two adjacent counties. All 
participants are residents of Germany and have been sampled in strata 
of age and sex from the local registries. In the baseline survey KORA S4, 
4,261 subjects have been examined. 3,080 subjects participated in a 7-
year follow-up examination of S4 in 2006-2008. Illumina HumanExome 
BeadChip was measured in KORA F4 participants.
CROATIA-Korcula
The CROATIA-Korcula (Zemunik et al.) study sampled Croatians from the 
Adriatic island of Korcula, between the ages of 18 and 88. The fieldwork 
was performed in 2007 in the eastern part of the island, targeting 
healthy volunteers from the town of Korčula and the villages of 
Lumbarda, Žrnovo and Račišće.
Lifelines
LifeLines (Scholtens et al.) is a multi-disciplinary prospective population-
based cohort study examining in a unique three-generation design the 
health and health-related behaviors of 165,000 persons living in the 
North East region of The Netherlands. It employs a broad range of 
investigative procedures in assessing the biomedical, socio-demographic, 
behavioral, physical and psychological factors which contribute to the 
health and disease of the general population, with a special focus on 
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multi-morbidity and complex genetics. Details of the protocol have been 
described elsewhere (https://www.lifelines.nl/lifelines-research/news). 
Standard 12-lead EKGs were recorded with CardioPerfect equipment 
(Cardio Control; currently Welch Allyn, Delft, The Netherlands) and 
digital measurements of the QT intervals were extracted.
MESA
The Multi-Ethnic Study of Atherosclerosis (MESA) (Bild et al.; Grove et 
al.) is a study of the characteristics of subclinical cardiovascular disease 
(disease detected non-invasively before it has produced clinical signs and 
symptoms) and the risk factors that predict progression to clinically overt 
cardiovascular disease or progression of the subclinical disease. The 
cohort is a diverse, population-based sample of 6,814 asymptomatic men 
and women aged 45-84. Approximately 38 percent of the recruited 
participants are white, 28 percent African-American, 22 percent 
Hispanic, and 12 percent Asian (predominantly of Chinese descent). 
Participants were recruited during 2000-2002 from 6 field centers across 
the U.S. (at Wake Forest University; Columbia University; Johns Hopkins 
University; the University of Minnesota; Northwestern University, and the 
University of California – Los Angeles). All underwent extensive initial 
physical examination and evaluation. The first examination was followed 
by 4 examination periods that were 17-20 months long.
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NEO
The Netherlands Epidemiology of Obesity (NEO) study (de Mutsert et al.): 
The NEO was designed for extensive phenotyping to investigate pathways 
that lead to obesity-related diseases. The NEO study is a population-
based, prospective cohort study that includes 6,671 individuals aged 45–
65 years, with an oversampling of individuals with overweight or obesity. 
At baseline, information on demography, lifestyle, and medical history 
have been collected by questionnaires. In addition, samples of 24-h 
urine, fasting and postprandial blood plasma and serum, and DNA were 
collected. Genotyping was performed using the Illumina 
HumanCoreExome chip, which was subsequently imputed to the 1000 
genome reference panel. Participants underwent an extensive physical 
examination, including anthropometry, electrocardiography, spirometry, 
and measurement of the carotid artery intima-media thickness by 
ultrasonography. In random subsamples of participants, magnetic 
resonance imaging of abdominal fat, pulse wave velocity of the aorta, 
heart, and brain, magnetic resonance spectroscopy of the liver, indirect 
calorimetry, dual energy X-ray absorptiometry, or accelerometry 
measurements were performed. The collection of data started in 
September 2008 and completed at the end of September 2012. 
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Participants are currently being followed for the incidence of obesity-
related diseases and mortality.
RS
The Rotterdam Elderly Study (Hofman, Brusselle, et al.) is a prospective 
cohort study in the Ommoord district in the city of Rotterdam, the 
Netherlands. Following the pilot in 1989, recruitment started in January 
1990. The main objectives of the Rotterdam Study were to investigate the 
risk factors of cardiovascular, neurological, ophthalmological and 
endocrine diseases in the elderly. Up to 2008, approximately 15,000 
subjects aged 45 years or over have been recruited. Participants were 
interviewed at home and went through an extensive set of examinations, 
bone mineral densiometry, including sample collections for in-depth 
molecular and genetic analyses. Examinations were repeated every 3-4 
years in potentially changing characteristics. Participants were followed 
for the most common diseases in the elderly, including coronary heart 
disease, heart failure and stroke, Parkinson's disease, Alzheimer's 
disease and other dementias, depression and anxiety disorders, macular 
degeneration and glaucoma, diabetes mellitus and osteoporosis.
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SHIP
The Study of Health In Pomerania (Völzke et al.) is a prospective 
longitudinal population-based cohort study in Western Pomerania 
assessing the prevalence and incidence of common diseases and their 
risk factors. SHIP encompasses the two independent cohorts SHIP and 
SHIP-TREND. Participants aged 20 to 79 with German citizenship and 
principal residency in the study area were recruited from a random 
sample of residents living in the three local cities, 12 towns as well as 17 
randomly selected smaller towns. Individuals were randomly selected 
stratified by age and sex in proportion to population size of the city, town 
or small towns, respectively. A total of 4,308 participants were recruited 
between 1997 and 2001 in the SHIP cohort. Between 2008 and 2012 a 
total of 4,420 participants were recruited in the SHIP-TREND cohort. 
Individuals were invited to the SHIP study centre for a computer-assisted 
personal interviews and extensive physical examinations.
TwinsUK
TwinsUK (Moayyeri et al.) is a nation-wide registry of volunteer twins in 
the United Kingdom, with about 12,000 registered twins (83% female, 
equal number of monozygotic and dizygotic twins, predominantly middle-
aged and older). Over the last 20 years, questionnaire and 
blood/urine/tissue samples have been collected on over 7,000 subjects, 
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as well as three comprehensive phenotyping assessments in the clinical 
facilities of the Department of Twin Research and Genetic Epidemiology, 
King's College London. The primary focus of study has been the genetic 
basis of healthy aging process and complex diseases, including 
cardiovascular, metabolic, musculoskeletal, and ophthalmologic 
disorders. Alongside the detailed clinical, biochemical, behavioral, and 
socio-economic characterization of the study population, the major 
strength of TwinsUK is availability of several 'omics' technologies for the 
participants. These include genome-wide scans of single nucleotide 
variants, next-generation sequencing, exome sequencing, epigenetic 
markers (MeDIP sequencing), gene expression arrays and RNA 
sequencing, telomere length measures, metabolomic profiles, and gut 
flora microbiomics.
UHP
The Utrecht Health Project (UHP) (Grobbee et al.) is an ongoing dynamic 
population study initiated in a newly developed large residential area in 
Leidsche Rijn, part of the city of Utrecht. All new inhabitants were invited 
by their general practitioner to participate in the UHP. Written informed 
consent was obtained and an individual health profile (IHP) was made by 
dedicated research nurses. The UHP study was approved by the Medical 
Ethical Committee of the University Medical Center, Utrecht, The 
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Netherlands. A large number of measures were taken, including 
anthropomorphic and blood pressure measurements, and each 
participant filled out a questionnaire. A 12-lead EKG was made at rest 
and digitally stored. PR, QRS, QT, and RR intervals were calculated 
automatically.
WHI
The Women's Health Initiative (WHI) (“Design of the Women’s Health 
Initiative Clinical Trial and Observational Study. The Women’s Health 
Initiative Study Group”; Anderson et al.) is a long-term national health 
study that has focused on The strategies for preventing heart disease, 
breast and colorectal cancers, and osteoporotic fractures in 
postmenopausal women (ref1, ref2). The WHI was designed as a set of 
randomized controlled clinical trials (CTs) and an observational study 
(OS). The CT (n = 68,132) included 3 overlapping components: the 
hormone therapy trials (n = 27,347), dietary modification trial (n = 
48,835), and calcium and vitamin D trial (n = 36,282). Eligible women 
could be part of several of the CT components. Women who were 
ineligible or unwilling to join the CT were invited to join the OS (n = 
93,676). All participants in the CT were administered EKGs every three 
years. In the current paper we include the baseline EKGs of women who 
were genotyped on the exomechip.
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YFS
The YFS (Raitakari et al.) is a population-based follow up-study started 
in 1980. The main aim of the YFS is to determine the contribution made 
by childhood lifestyle, biological and psychological measures to the risk 
of cardiovascular diseases in adulthood. In 1980, over 3,500 children 
and adolescents all around Finland participated in the baseline study. 
The follow-up studies have been conducted mainly with 3-year intervals. 
The latest 30-year follow-up study was conducted in 2010-11 (ages 33-
49 years) with 2,063 participants. The study was approved by the local 
ethics committees (University Hospitals of Helsinki, Turku, Tampere, 
Kuopio and Oulu) and was conducted following the guidelines of the 




Chapter 4: Metabochip and PROSe-ICD
4.1 Background
SCD is death caused by loss of heart function in the absence of 
clinical features that would bring a victim to medical attention. 
Importantly, SCD lacks symptoms 24 hours before the incident, however 
SCD does have risk factors that can be evaluated. There are between 
180,000 and 450,000 cases of SCD in the United States of America 
annually (Deo and Albert). ICDs can be used to prevent SCD in patients 
with systolic heart failure. The World Society of Arrhythmia found that 
there were 133,262 ICD implants in the United States in 2009 alone 
(Mond and Proclemer). However, ICDs administer therapy in only a 
minority of patients, about 20% in our data. The cost assessed for 
reimbursement is approximately $40,000 per device in 2006 (Stevenson). 
This represents a significant shortcoming in the clinical selection criteria 
for patients at greatest risk for SCD. Currently the primary clinical 
metric used to determine if a patient should receive an ICD is low left 
ventricular ejection fraction. We wish to find out if we can use genetics to 
predict if an ICD will be useful for a patient.
4.2 Population
We use data from the PRospective Observational Study of 
Implantable Cardioverter-Defibrillators (PROSe-ICD) cohort (Cheng et 
al.). This population consists of patients receiving ICDs for primary 
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prevention of SCD from one of four centers: the Johns Hopkins Hospital 
and Bayview Medical Center, Baltimore, MD (JHU), the University of 
Maryland Hospital, Baltimore, MD (UMD), the Virginia Commonwealth 
University Hospital, Richmond, VA (VCU), or the Washington Hospital 
Center, Washington, DC (WHC). Inclusion in the study required a history 
of acute myocardial infarction, non-ischemic left ventricle dysfunction for 
at least 9 months, left ventricle ejection fraction less than or equal to 
35%, and have an ICD. These patients were followed every 6 months 
since their operation in person or by phone. Blood samples were 
collected at each in person follow-up. Patients were evaluated for six 
primary phenotypes: all-cause mortality (death), all-cause mortality 
censored at first appropriate ICD shock (death2), appropriate ICD shock 
(appshock), appropriate ICD therapy (apptherapy), inappropriate ICD 
shock (inappshock), and inappropriate ICD therapy (inapptherapy). 
Appropriateness is defined as the first incident adjudicated by two of 
three cardiologists as lethal without intervention. ICD therapy is defined 
as antitachycardia pacing or defibrillation shock. Baseline 12-lead Bazett 
corrected QT interval was measured for all patients. Demographics 
summarized in Table 4.1.
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Table 4.1: PROSe-ICD Demographics
Demographic information for the PROSe-ICD cohort. For all individuals 
and broken down by ethnicity, EA=European-ancestry, AA=African 
Americans.
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Phenotype All EA AA
Patients N (%) 1066 (100) 638 (59.85) 428 (40.15)
Female N (%) 284 (26.64) 139 (21.79) 145 (33.88)
Age years mean±sd 60.76±12.71 63.63±11.68 56.48±12.98
Age min-max 20.48-85.61 26.06-85.61 20.48-83.33
Center JHU UMD VCU 
WHC Number
690 80 68 
228
479 34 27 98




580 (54.41) 411 (64.42) 169 (39.49)
Non-ischemic 
Cardiomyopathy N (%)
519 (48.69) 249 (39.03) 270 (63.08)
BMI kg/m2 mean±sd 29.8±6.557 29.28±5.906 30.57±7.36
Height cm mean±sd 173.4±9.458 174.3±9.069 172.1±9.878
Death N (%) 374 (35.08) 238 (37.3) 136 (31.78)
Time to Death years 
mean±sd
6.386±3.092 6.467±3.149 6.266±3.005
Death2 N (%) 318 (29.83) 199 (31.19) 119 (27.8)
Time to Death2 years 
mean±sd
5.848±3.206 5.843±3.267 5.856±3.116
Appshock N (%) 157 (14.73) 105 (16.46) 52 (12.15)
Time to Appshock years 
mean±sd
4.598±3.003 4.718±3.131 4.419±2.796
Apptherapy N (%) 217 (20.36) 133 (20.85) 84 (19.63)
Time to Apptherapy years 
mean±sd
4.384±3.001 4.558±3.156 4.125±2.736
Inappshock N (%) 123 (11.54) 70 (10.97) 53 (12.38)
Time to Inappshock years 
mean±sd
4.479±3.06 4.7±3.194 4.149±2.819
Inapptherapy N (%) 155 (14.54) 86 (13.48) 69 (16.12)
Time to Inapptherapy 
years mean±sd
4.395±3.051 4.636±3.188 4.037±2.801
QTc mean±sd 458.9±43.51 457.3±41.22 461.3±46.68
QTc min-max 263-696 301-661 263-696
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4.3 Genotyping and Imputation
All patients were genotyped using the Illumina Cardio-MetaboChip 
(metabochip) containing over 200,000 SNPs associated with metabolic, 
atherosclerotic, and/or cardiovascular disease traits (Voight et al.). 
Associated SNPs were contributed by the following 7 large consortiums: 
CARDIoGRAM (coronary artery disease), DIAGRAM (type 2 diabetes), 
GIANT (height and weight), MAGIC (glycemic traits), Lipids (lipids), ICBP-
GWAS (blood pressure), and QTIGC (QT interval). Standard QC was 
performed using Plink (Purcell et al.) removing SNPs with greater than 
5% missingness and samples with greater than 10% missingness, miss-
matched sex, contaminated samples defined by over representation in 
nearest neighbor test, and genetic outliers defined by separation from 
HapMap3 reference population in a PCA plot (miss-matched ethnicity).
This genotyping data was then used to seed an imputation to the 
1000G phase3 reference using the ShapeIT (Delaneau et al.) and 
Impute2 (Howie, Donnelly, and Marchini) software. Unfiltered, this 
resulted in over 81 million genetic variants typed for each patient. 
However, using all these variants is not our intention. The metabochip 
focuses on certain regions of the genome while neglecting others due to 
its focus on metabolic, atherosclerotic, and/or cardiovascular disease 
traits. This makes for a low quality imputation in those neglected 
regions, which in this case is most of the genome. Filtering will be 
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required. Our intention behind imputing is to allow for easy meta-
analyses with other cohorts that were genotyped with other genotyping 
chips. See section 4.6 for more details.
4.4 Association Model
Since this is a longitudinal cohort with time to event data, the 
CoxPH models is used to determine if a genetic variants effect the 
phenotype. Covariates include age, sex, center, whether the instigating 
cardiomyopathy was ischemic, and 4 Principal Components (PCs) to 
account for population substructure. The software FAST is used to run 
this model (Chanda et al.). For the QTc phenotype, a standard 
linear/additive association model is used, including covariates above and 
additionally height and BMI. This model was also run using the FAST 
software.
4.5 Results
Due to the limitations discussed in section 4.3 above, results 
shown below are filtered for FAST’s calculated effective sample size 
greater than or equal to 100 individuals. Displayed are Manhattan and 
QQ plots for the 6 primary phenotypes and QTc for European-ancestry 
and African American individuals (Figures 4.1-4.14).
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Figure 4.1: PROSe-ICD AA Appshock FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with African Americans from the 
PROSe-ICD cohort and the outcome phenotype of appropriate ICD shock. 
CoxPH model run using the FAST software. Results limited to effective 
sample size greater or equal to 100 individuals. X-axis is the human 
genome, autosomes-only. Y-axis is the significance level, -log10 of the p-
value. The green bar represents the Bonferroni corrected significance 
level, p-value < 0.05/1000000. “L” is the genomic inflation factor, 
lambda. “Samples” is the maximum effective sample size calculated in 
FAST. Quantile-quantile plot of results in Manhattan plot is inset into 
upper right. X-axis represents expected significance under the null 
hypothesis. Y-axis is observed significance ordered by -log10 p-value. 
Early departure from the 45-degree line in black is indicative of an 
inflated test statistic, not seen here.
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Figure 4.2: PROSe-ICD AA Apptherapy FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with African Americans from the 
PROSe-ICD cohort and the outcome phenotype of appropriate ICD 
therapy. CoxPH model run using the FAST software. Results limited to 
effective sample size greater or equal to 100 individuals. X-axis is the 
human genome, autosomes-only. Y-axis is the significance level, -log10 
of the p-value. The green bar represents the Bonferroni corrected 
significance level, p-value < 0.05/1000000. “L” is the genomic inflation 
factor, lambda. “Samples” is the maximum effective sample size 
calculated in FAST. Quantile-quantile plot of results in Manhattan plot is 
inset into upper right. X-axis represents expected significance under the 
null hypothesis. Y-axis is observed significance ordered by -log10 p-
value. Early departure from the 45-degree line in black is indicative of an 
inflated test statistic, not seen here.
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Figure 4.3: PROSe-ICD AA Death2 FAST CoxPH N>=100 Manhattan 
Plot
Manhattan plot of GWAS results with African Americans from the 
PROSe-ICD cohort and the outcome phenotype of all-cause mortality, 
censored at first appropriate ICD shock. CoxPH model run using the 
FAST software. Results limited to effective sample size greater or equal to 
100 individuals. X-axis is the human genome, autosomes-only. Y-axis is 
the significance level, -log10 of the p-value. The green bar represents the 
Bonferroni corrected significance level, p-value < 0.05/1000000. “L” is 
the genomic inflation factor, lambda. “Samples” is the maximum effective 
sample size calculated in FAST. Quantile-quantile plot of results in 
Manhattan plot is inset into upper left. X-axis represents expected 
significance under the null hypothesis. Y-axis is observed significance 
ordered by -log10 p-value. Early departure from the 45-degree line in 
black is indicative of an inflated test statistic, not seen here.
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Figure 4.4: PROSe-ICD AA Death FAST CoxPH N>=100 Manhattan 
Plot
Manhattan plot of GWAS results with African Americans from the 
PROSe-ICD cohort and the outcome phenotype of all-cause mortality. 
CoxPH model run using the FAST software. Results limited to effective 
sample size greater or equal to 100 individuals. X-axis is the human 
genome, autosomes-only. Y-axis is the significance level, -log10 of the p-
value. The green bar represents the Bonferroni corrected significance 
level, p-value < 0.05/1000000. “L” is the genomic inflation factor, 
lambda. “Samples” is the maximum effective sample size calculated in 
FAST. Quantile-quantile plot of results in Manhattan plot is inset into 
upper right. X-axis represents expected significance under the null 
hypothesis. Y-axis is observed significance ordered by -log10 p-value. 
Early departure from the 45-degree line in black is indicative of an 
inflated test statistic, not seen here.
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Figure 4.5: PROSe-ICD AA Inappshock FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with African Americans from the 
PROSe-ICD cohort and the outcome phenotype of inappropriate ICD 
shock. CoxPH model run using the FAST software. Results limited to 
effective sample size greater or equal to 100 individuals. X-axis is the 
human genome, autosomes-only. Y-axis is the significance level, -log10 
of the p-value. The green bar represents the Bonferroni corrected 
significance level, p-value < 0.05/1000000. “L” is the genomic inflation 
factor, lambda. “Samples” is the maximum effective sample size 
calculated in FAST. Quantile-quantile plot of results in Manhattan plot is 
inset into upper right. X-axis represents expected significance under the 
null hypothesis. Y-axis is observed significance ordered by -log10 p-
value. Early departure from the 45-degree line in black is indicative of an 
inflated test statistic, not seen here.
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Figure 4.6: PROSe-ICD AA Inapptherapy FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with African Americans from the 
PROSe-ICD cohort and the outcome phenotype of inappropriate ICD 
therapy. CoxPH model run using the FAST software. Results limited to 
effective sample size greater or equal to 100 individuals. X-axis is the 
human genome, autosomes-only. Y-axis is the significance level, -log10 
of the p-value. The green bar represents the Bonferroni corrected 
significance level, p-value < 0.05/1000000. “L” is the genomic inflation 
factor, lambda. “Samples” is the maximum effective sample size 
calculated in FAST. Quantile-quantile plot of results in Manhattan plot is 
inset into upper right. X-axis represents expected significance under the 
null hypothesis. Y-axis is observed significance ordered by -log10 p-
value. Early departure from the 45-degree line in black is indicative of an 
inflated test statistic, not seen here.
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Figure 4.7: PROSe-ICD AA QTc12 FAST CoxPH N>=100 Manhattan 
Plot
Manhattan plot of GWAS results with African Americans from the 
PROSe-ICD cohort and the outcome phenotype of 12-lead Bazett 
corrected QT interval. Linear association model run using the FAST 
software. Results limited to effective sample size greater or equal to 100 
individuals. X-axis is the human genome, autosomes-only. Y-axis is the 
significance level, -log10 of the p-value. The green bar represents the 
Bonferroni corrected significance level, p-value < 0.05/1000000. “L” is 
the genomic inflation factor, lambda. “Samples” is the maximum effective 
sample size calculated in FAST. Quantile-quantile plot of results in 
Manhattan plot is inset into upper left. X-axis represents expected 
significance under the null hypothesis. Y-axis is observed significance 
ordered by -log10 p-value. Early departure from the 45-degree line in 
black is indicative of an inflated test statistic, not seen here.
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Figure 4.8: PROSe-ICD EA Appshock FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with Caucasians from the PROSe-ICD 
cohort and the outcome phenotype of appropriate ICD shock. CoxPH 
model run using the FAST software. Results limited to effective sample 
size greater or equal to 100 individuals. X-axis is the human genome, 
autosomes-only. Y-axis is the significance level, -log10 of the p-value. 
The green bar represents the Bonferroni corrected significance level, p-
value < 0.05/1000000. “L” is the genomic inflation factor, lambda. 
“Samples” is the maximum effective sample size calculated in FAST. 
Quantile-quantile plot of results in Manhattan plot is inset into upper 
left. X-axis represents expected significance under the null hypothesis. 
Y-axis is observed significance ordered by -log10 p-value. Early 
departure from the 45-degree line in black is indicative of an inflated test 
statistic, not seen here.
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Figure 4.9: PROSe-ICD EA Apptherapy FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with Caucasians from the PROSe-ICD 
cohort and the outcome phenotype of appropriate ICD therapy. CoxPH 
model run using the FAST software. Results limited to effective sample 
size greater or equal to 100 individuals. X-axis is the human genome, 
autosomes-only. Y-axis is the significance level, -log10 of the p-value. 
The green bar represents the Bonferroni corrected significance level, p-
value < 0.05/1000000. “L” is the genomic inflation factor, lambda. 
“Samples” is the maximum effective sample size calculated in FAST. 
Quantile-quantile plot of results in Manhattan plot is inset into upper 
right. X-axis represents expected significance under the null hypothesis. 
Y-axis is observed significance ordered by -log10 p-value. Early 
departure from the 45-degree line in black is indicative of an inflated test 
statistic, not seen here.
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Figure 4.10: PROSe-ICD EA Death2 FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with Caucasians from the PROSe-ICD 
cohort and the outcome phenotype of all-cause mortality, censored at 
first appropriate ICD shock. CoxPH model run using the FAST software. 
Results limited to effective sample size greater or equal to 100 
individuals. X-axis is the human genome, autosomes-only. Y-axis is the 
significance level, -log10 of the p-value. The green bar represents the 
Bonferroni corrected significance level, p-value < 0.05/1000000. “L” is 
the genomic inflation factor, lambda. “Samples” is the maximum effective 
sample size calculated in FAST. Quantile-quantile plot of results in 
Manhattan plot is inset into upper right. X-axis represents expected 
significance under the null hypothesis. Y-axis is observed significance 
ordered by -log10 p-value. Early departure from the 45-degree line in 
black is indicative of an inflated test statistic, not seen here.
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Figure 4.11: PROSe-ICD EA Death FAST CoxPH N>=100 Manhattan 
Plot
Manhattan plot of GWAS results with Caucasians from the PROSe-ICD 
cohort and the outcome phenotype of all-cause mortality. CoxPH model 
run using the FAST software. Results limited to effective sample size 
greater or equal to 100 individuals. X-axis is the human genome, 
autosomes-only. Y-axis is the significance level, -log10 of the p-value. 
The green bar represents the Bonferroni corrected significance level, p-
value < 0.05/1000000. “L” is the genomic inflation factor, lambda. 
“Samples” is the maximum effective sample size calculated in FAST. 
Quantile-quantile plot of results in Manhattan plot is inset into upper 
right. X-axis represents expected significance under the null hypothesis. 
Y-axis is observed significance ordered by -log10 p-value. Early 
departure from the 45-degree line in black is indicative of an inflated test 
statistic, not seen here.
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Figure 4.12: PROSe-ICD EA Inappshock FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with Caucasians from the PROSe-ICD 
cohort and the outcome phenotype of inappropriate ICD shock. CoxPH 
model run using the FAST software. Results limited to effective sample 
size greater or equal to 100 individuals. X-axis is the human genome, 
autosomes-only. Y-axis is the significance level, -log10 of the p-value. 
The green bar represents the Bonferroni corrected significance level, p-
value < 0.05/1000000. “L” is the genomic inflation factor, lambda. 
“Samples” is the maximum effective sample size calculated in FAST. 
Quantile-quantile plot of results in Manhattan plot is inset into upper 
right. X-axis represents expected significance under the null hypothesis. 
Y-axis is observed significance ordered by -log10 p-value. Early 
departure from the 45-degree line in black is indicative of an inflated test 
statistic, not seen here.
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Figure 4.13: PROSe-ICD EA Inapptherapy FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with Caucasians from the PROSe-ICD 
cohort and the outcome phenotype of inappropriate ICD therapy. CoxPH 
model run using the FAST software. Results limited to effective sample 
size greater or equal to 100 individuals. X-axis is the human genome, 
autosomes-only. Y-axis is the significance level, -log10 of the p-value. 
The green bar represents the Bonferroni corrected significance level, p-
value < 0.05/1000000. “L” is the genomic inflation factor, lambda. 
“Samples” is the maximum effective sample size calculated in FAST. 
Quantile-quantile plot of results in Manhattan plot is inset into upper 
right. X-axis represents expected significance under the null hypothesis. 
Y-axis is observed significance ordered by -log10 p-value. Early 
departure from the 45-degree line in black is indicative of an inflated test 
statistic, not seen here.
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Figure 4.14: PROSe-ICD EA QTc12 FAST CoxPH N>=100 
Manhattan Plot
Manhattan plot of GWAS results with Caucasians from the PROSe-ICD 
cohort and the outcome phenotype of 12-lead Bazett corrected QT 
interval. Linear association model run using the FAST software. Results 
limited to effective sample size greater or equal to 100 individuals. X-axis 
is the human genome, autosomes-only. Y-axis is the significance level, 
-log10 of the p-value. The green bar represents the Bonferroni corrected 
significance level, p-value < 0.05/1000000. “L” is the genomic inflation 
factor, lambda. “Samples” is the maximum effective sample size 
calculated in FAST. Quantile-quantile plot of results in Manhattan plot is 
inset into upper right. X-axis represents expected significance under the 
null hypothesis. Y-axis is observed significance ordered by -log10 p-
value. Early departure from the 45-degree line in black is indicative of an 




The only variant to reach genome-wide significance is 
rs148676350 in the African American QTc association. The locus has 
never been associated with QT interval in either the QT-IGC study or the 
QT interval study discussed in Chapter 3, although the variant itself was 
in neither study. rs148676350 is located in the 3’ UTR of ZNF3 and has 
a coded allele frequency of 0.24, a Quality score of 0.71, an effective 
sample size of 109.6, an effect size estimate of 25.85, and a p-value of 
2.40x10^-8.
We performed a power calculation to determine what we are likely 
to find using this study. We are well-powered to detect hazard ratios over 
2.3 for SNPs with minor allele frequencies greater than 10%. If we had 10 
times the sample size, we could detect hazard ratios over 1.3. Previously 
published genome-wide association studies indicate finding a common 
variant with hazard ratios that high is unlikely. Therefore, our results are 
not unexpected. We simply lack power to detect a genetic effect. To 
remedy this, we are working on building a consortium to increase sample 
size. We have started working with CardioDX’s DISCERN cohort to this 




I have discussed three projects I undertook in the field of human 
genetics during the course of my graduate studies. The first was an 
investigation of the impact of genome-wide heterozygosity on overall 
longevity in humans. We consider “longevity” to be the lower risk of death 
within a time period. We found evidence that the protective effect of 
increased heterozygosity seen in lower organisms is present in humans. 
We estimate that within a single population, every standard deviation of 
heterozygosity an individual has over the mean decreases that person’s 
risk of death by within a given time period 1.57%. Our data shows this to 
be true even if the population itself has reduced mean heterozygosity. We 
observed a broad positive impact of genomic diversity on human survival 
demonstrated by the consistency we observed between European and 
African ancestry, males and females, and major causes of death. This 
project was concerned with human genetics at a population level. It is 
not a goal of this study to dissect the association to locate the underlying 
genetic and biologic causes or identify genes and pathways that 
contribute to the association.
The second project investigated of the role of coding variants in 
regulating QT Interval, a predictor of SCD. Our approach of focusing on 
coding variants identified 10 novel loci associated with QT/JT intervals, 
and highlighted the role of 17 specific genes, 7 of which were from novel 
loci. In addition to previously implicated pathways of potassium ion 
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regulation, sodium ion regulation, calcium ion regulation, and autonomic 
control of QT interval, our analyses highlighted a role for the internal 
structure of myocytes and interconnection of myocytes in modulating QT 
interval duration. We called this regulation mechanical control of QT 
interval. This project focused on a particular disease, SCD, by looking at 
one of its related phenotypes, QT interval, and applies human genetics to 
understand an individual’s risk for this disease. The goal was finding 
individual genes that control electrophysiology and by extension that 
effect a person’s risk for SCD and we found 17 genes effecting QT/JT 
intervals. This represents a narrowing of focus compared to the 
population-based question in the first project. These new discoveries will 
likely allow for the development of novel vectors for the prevention of 
lethal ventricular arrhythmias and SCD.
The last project was an investigation of the utility of genetics in 
predicting ICD therapy incidence. An accurate prediction can be used to 
evaluate if a particular patient should undergo surgery to receive an ICD. 
Unfortunately, our sample size was too limited to find meaningful 
results. We performed a power calculation to determine what we are 
likely to find using data from the PROSe-ICD cohort and found that we 
are well powered to detect hazard ratios over 2.3 in SNPs with minor 
allele frequencies greater than 10%. Judging by previously published 
genome-wide association studies, finding a common variant with hazard 
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ratios that high is unlikely. Sample size drives discovery and ours was 
too small for the expected hazard ratios. To remedy this, we are working 
on building a consortium to increase sample size. This project was 
concerned with applying human genetics to a clinical question. Finding 
an answer to this question would have directly affected the actions taken 
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